Overview of HIV associated HIV Infections

ID Literature Title Group
1 17500586 HIV-1 subtype B protease and reverse transcriptase amino acid covariation
Mutation
2 39420358 Transmitted drug resistance and molecular transmission network among treatment-naive HIV-1 patients in Wenzhou, China, 2020-2023
Mutation
3 39431267 Design, Synthesis, and Biological Evaluation of Darunavir Analogs as HIV-1 Protease Inhibitors
Mutation
4 39459843 Preclinical Profile of the HIV-1 Maturation Inhibitor VH3739937
Mutation
5 39459930 Frequency of Major Transmitted Integrase Resistance in Poland Remains Low Despite Change in Subtype Variability
Mutation
6 39459974 The HIV-1 vpr R77Q Mutant Induces Apoptosis, G(2) Cell Cycle Arrest, and Lower Production of Pro-Inflammatory Cytokines in Human CD4+ T Cells
Mutation
7 39491355 Prevalence of integrase strand transfer inhibitor resistance in people living with HIV and virological failure
Mutation
8 39493858 Epidemiological dynamics and molecular characterization of HIV drug resistance in eastern China from 2020 to 2023
Mutation
9 39512940 Low prevalence of archived integrase strand transfer inhibitors resistance associated mutations in Botswana before the roll out of dolutegravir based first line antiretroviral therapy
Mutation
10 39552198 Analysis of genotype resistance and HIV-1 transmission risk in HIV-1-infected men who have sex with men in Guiyang, China
Mutation
11 39563829 Invention of VH-937, a Potent HIV-1 Maturation Inhibitor with the Potential for Infrequent Oral Dosing in Humans
Mutation
12 39599830 Spectrum of Non-Nucleoside Reverse Transcriptase Inhibitor-Associated Drug Resistance Mutations in Persons Living with HIV-1 Receiving Rilpivirine
Mutation
13 17559687 Predictive factors of virological success to salvage regimens containing protease inhibitors in HIV-1 infected children
Mutation
14 17620130 Protease inhibitor associated mutations compromise the efficacy of therapy in human immunodeficiency virus-1 (HIV-1) infected pediatric patients: a cross-sectional study
Mutation
15 39612239 Functional variability of Nef in antagonizing SERINC5 during acute to chronic HIV-1 infection
Mutation
16 39693152 Neuropathy among drug resistant HIV Patients treated in Jakarta
Mutation
17 39707787 HIV-2 drug resistance genotyping and viral load among HIV-2 infected adults in Burkina Faso, West Africa
Mutation
18 39772163 Predictive Efficacy of Dual Therapies Combining Integrase Strand Transfer Inhibitors with Second-Generation Non-Nucleoside Reverse Transcriptase Inhibitors Following HIV-1 Treatment Failure in Cameroon: Implications for the Use of a Long-Acting Therapeutic Strategy in Low- and Middle-Income Countries
Mutation
19 17630831 HIV-1 Vpr-mediated G2 arrest involves the DDB1-CUL4AVPRBP E3 ubiquitin ligase
Mutation
20 39772167 Virulence and Replicative Fitness of HIV-1 Transmitted/Founder (T/F) Viruses Harbouring Drug Resistance-Associated Mutation
Mutation
21 39772195 Thymidine Analogue Mutations with M184V Significantly Decrease Phenotypic Susceptibility of HIV-1 Subtype C Reverse Transcriptase to Islatravir
Mutation
22 39772259 Genetic Diversity and Antiretroviral Resistance in HIV-1-Infected Patients Newly Diagnosed in Cabo Verde
Mutation
23 39786501 Major role of dolutegravir in the emergence of the S147G integrase resistance mutation
Mutation
24 39807872 HIV-1 DNA Genotypic Drug Resistance Testing Guides Antiretroviral Therapy in Patients with Low-Level Viremia
Mutation
25 17634131 Phenotype and envelope gene diversity of nef-deleted HIV-1 isolated from long-term survivors infected from a single source
Mutation
26 39811907 No virological failure in patients living with HIV with past NNRTI resistance-associated mutations switched to doravirine-containing regimens
Mutation
27 17697319 High genetic variability of HIV-1 in female sex workers from Argentina
Mutation
28 39816057 Prevalence of major INSTI and HIV-1 drug resistance mutations in pre- and antiretroviral-treated patients in Indonesia
Mutation
29 39835338 Prevalence of drug resistance mutations in low-level viremia patients under antiretroviral therapy in Southwestern China: a cross-sectional study
Mutation
30 39849846 Assessing phenotypic effect of integrase strand-transfer inhibitor (INSTI)-based resistance substitutions associated with failures on cabotegravir
Mutation
31 39861009 HIV Drug Resistance Profile in Clients Experiencing Treatment Failure After the Transition to a Dolutegravir-Based First-Line Antiretroviral Treatment Regimen in Mozambique
Mutation
32 17710130 Differential drug resistance acquisition in HIV-1 of subtypes B and C
Mutation
33 39861858 Tenofovir and Doravirine Are Potential Reverse-Transcriptase Analogs in Combination with the New Reverse-Transcriptase Translocation Inhibitor (Islatravir) Among Treatment-Experienced Patients in Cameroon: Designing Future Treatment Strategies for Low- and Middle-Income Countries
Mutation
34 39861910 Comparative Analyses of Antiviral Potencies of Second-Generation Integrase Strand Transfer Inhibitors (INSTIs) and the Developmental Compound 4d Against a Panel of Integrase Quadruple Mutants
Mutation
35 39866283 Pretreatment HIV Drug Resistance to Integrase Strand Transfer Inhibitors Among Newly Diagnosed HIV Individuals - China, 2018-2023
Mutation
36 39872809 Learning From Full Characterization of HIV Proviruses in People Receiving Long-Acting Cabotegravir/Rilpivirine With a History of Replication on the Antiretroviral Classes
Mutation
37 39873394 Resistance Analyses in Heavily Treatment-Experienced People With HIV Treated With the Novel HIV Capsid Inhibitor Lenacapavir After 2 Years
Mutation
38 39879199 HIV-1 resistance mutations and genetic diversity among children failing antiretroviral treatment in five healthcare facilities in Benin, West Africa
Mutation
39 39881519 Subtypes A1 and D, and recombinant HIV-1 natural polymorphisms associated with lenacapavir drug resistance in Uganda
Mutation
40 39885593 Brief communication: virological outcomes and dolutegravir resistance mutations in HIV-infected patients: a multicenter retrospective cohort study in Mozambique
Mutation
41 39899370 Impact of INSTI on a Drug-Resistant Mutation (S68S Insertion) in a Patient Infected with HIV-1 CRF06_cpx
Mutation
42 39912770 Drug resistance testing at regimen failure in individuals diagnosed with HIV-1 between 2010 and 2018 in Israel
Mutation
43 39923901 Hybrid next-generation sequencing protocol for testing HIV-2 drug resistance
Mutation
44 18177204 Enhancing exposure of HIV-1 neutralization epitopes through mutations in gp41
Mutation
45 39930490 Outcomes of switching from protease inhibitor-based antiretroviral therapy to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in virologically suppressed adults with nucleos(t)ide analogue resistance- a phase IV randomised, open-label study (PIBIK study)
Mutation
46 18221530 Multiple independent origins of a protease inhibitor resistance mutation in salvage therapy patients
Mutation
47 18271957 Identification of a novel resistance (E40F) and compensatory (K43E) substitution in HIV-1 reverse transcriptase
Mutation
48 39935964 Prevalence of Naturally Occurring HIV-1 Capsid Inhibitor Resistance-Related Mutations in Antiretroviral Therapy-Naive and -Experienced Individuals in Taiwan
Mutation
49 39947098 Transmission of Dolutegravir resistance in treatment-naive individuals with HIV-1: A cohort study
Mutation
50 39960065 Insights into the interaction mechanism of first-generation HIV-1 protease inhibitors with wild-type and mutant (D30N and L76V) enzymes through in-silico based approach
Mutation
51 39970315 Brief Report: New HIV Diagnoses in PrEP-Experienced and PrEP-Naive Persons in the ICONA Cohort
Mutation
52 40005688 Drug Resistance Mutations (DRMs) for Long-Acting Injectable Cabotegravir and Rilpivirine (CAB/RPV LAI) in the HIV-1 Subtype A6 Epidemic in Poland
Mutation
53 40007000 First Reported Case of Integrase Strand Transfer Inhibitor Resistance in Suriname: Unusual Drug Resistance Mutations Following Exposure to Dolutegravir
Mutation
54 40034260 Prediction of the Co-receptor usage of the main worldwide HIV-1 subtypes, CRF, and CRF35-AD in Iranian patients via the five genotypic tools
Mutation
55 40052565 Dolutegravir/Lamivudine for Maintenance of Virological Suppression in Persons with Historical Suspected or Confirmed Resistance to Lamivudine: Week 48 Results of a Single-Arm, Open-Label, Multicentre, Phase IIA Clinical Trial
Mutation
56 40055750 Identification of a novel small-molecule inhibitor of the HIV-1 reverse transcriptase activity with a non-nucleoside mode of action
Mutation
57 40066069 Drug resistance mutations to integrase inhibitors, proteinase, and reverse transcriptase inhibitors in newly diagnosed HIV-1 infections in Hebei province, China, 2018-2022
Mutation
58 40109100 Susceptibility to Lenacapavir Among Newly Diagnosed HIV-Positive Patients Followed Up in Mozambique That Presented With Primary Antiretroviral Resistance to Other Classes
Mutation
59 40137693 Computational and Population-Based HLA Permissiveness to HIV Drug Resistance-Associated Mutations
Mutation
60 40139311 Kinetic Investigation of Resistance to Islatravir Conferred by Mutations in HIV-1 Reverse Transcriptase
Mutation
61 40207163 High concordance of human immunodeficiency virus-1 genotypic drug resistance generated from paired cerebrospinal fluid and plasma in antiretroviral therapy -naive or -experienced patients
Mutation
62 40223733 Phenotypic Characterization of Replication-Impaired Lenacapavir-Resistant HIV Clinical Isolates
Mutation
63 18304321 Transmitted drug resistance, selection of resistance mutations and moderate antiretroviral efficacy in HIV-2: analysis of the HIV-2 Belgium and Luxembourg database
Mutation
64 40231850 Structural and mechanistic bases for resistance of the M66I capsid variant to lenacapavir
Mutation
65 40242261 Pretreatment HIV-1 Drug Resistance Among Newly Diagnosed People in Eastern Ethiopia
Mutation
66 40253369 Characteristics of molecular epidemiology and transmitted drug resistance among newly diagnosed HIV-1 infections in Lishui, China from 2020 to 2023
Mutation
67 40254262 Combined doravirine and islatravir cooperate to inhibit NRTI and NNRTI resistant HIV-1 in vitro
Mutation
68 40284921 Temporal Trends in HIV-1 Subtypes and Antiretroviral Drug Resistance Mutations in Istanbul, Turkiye (2021-2024): A Next-Generation Sequencing Study
Mutation
69 40297528 HIV-1 cross-resistance to second-generation non-nucleoside reverse transcriptase inhibitors among individuals failing antiretroviral therapy in Cameroon: implications for the use of long-acting treatment regimens in low- and middle-income countries
Mutation
70 40314140 Viral suppression after failure of PI-based ART among adolescents and youths with and without drug resistance mutations: a longitudinal analysis in Tanzania
Mutation
71 40333122 The Prevalence of Pretreatment Drug Resistance and Transmission Networks Among Newly Diagnosed HIV-1-Infected Individuals in Nanning, Guangxi, China
Mutation
72 40340650 Divergent transmission dynamics and drug resistance evolution of HIV-1 CRF01_AE and CRF07_BC in Tianjin, China (2013-2022)
Mutation
73 18335052 Conservation patterns of HIV-1 RT connection and RNase H domains: identification of new mutations in NRTI-treated patients
Mutation
74 40356938 Longer-term virologic outcomes on tenofovir-lamivudine-dolutegravir in second-line ART
Mutation
75 40358920 Investigation of Integrase Inhibitor Resistance Mutations in gp41 in Clinical Samples
Mutation
76 17194486 Drug-resistant HIV-1 prevalence in patients newly diagnosed with HIV/AIDS in Japan
Mutation
77 18052601 N348I in the connection domain of HIV-1 reverse transcriptase confers zidovudine and nevirapine resistance
Mutation
78 28099515 Polymorphisms and Mutational Covariation Associated with Death in a Prospective Cohort of HIV/AIDS Patients Receiving Long-Term ART in China
Mutation
79 29698467 HIV-1 genetic transmission networks among men who have sex with men in Kunming, China
Mutation
80 30061964 Antiretroviral resistance among HIV-1 patients on first-line therapy attending a comprehensive care clinic in Kenyatta National Hospital, Kenya: a retrospective analysis
Mutation
81 18369479 Transmission of HIV-1 CTL escape variants provides HLA-mismatched recipients with a survival advantage
Mutation
82 30442114 Research on the treatment effects and drug resistances of long-term second-line antiretroviral therapy among HIV-infected patients from Henan Province in China
Mutation
83 18419497 Plasma drug concentrations and virologic evaluations after stopping treatment with nonnucleoside reverse-transcriptase inhibitors in HIV type 1-infected children
Mutation
84 18547911 Connection domain mutations N348I and A360V in HIV-1 reverse transcriptase enhance resistance to 3'-azido-3'-deoxythymidine through both RNase H-dependent and -independent mechanisms
Mutation
85 31190911 Antiretroviral drug resistance mutations among patients failing first-line treatment in Hanoi, Vietnam
Mutation
86 31574109 Major drug resistance mutations to HIV-1 protease inhibitors (PI) among patients exposed to PI class failing antiretroviral therapy in Sao Paulo State, Brazil
Mutation
87 31767136 Indazolyl-substituted piperidin-4-yl-aminopyrimidines as HIV-1 NNRTIs: Design, synthesis and biological activities
Mutation
88 31920003 Highly drug-resistant HIV-1 protease reveals decreased intra-subunit interactions due to clusters of mutations
Mutation
89 32218587 Characterization of HIV-1 genetic diversity and antiretroviral resistance in the state of Maranhao, Northeast Brazil
Mutation
90 32280691 HIV-1 Drug Resistance, Distribution of Subtypes, and Drug Resistance-Associated Mutations in Virologic Failure Individuals in Chengdu, Southwest China, 2014-2016
Mutation
91 32295123 Molecular Epidemiology of the HIV-1 Subtype B Sub-Epidemic in Bulgaria
Mutation
92 18570675 Prevalence of reverse transcriptase and protease mutations associated with antiretroviral drug resistance among drug-naive HIV-1 infected pregnant women in Kagera and Kilimanjaro regions, Tanzania
Mutation
93 32368103 HIV-1 Drug Resistance in ART-Naive Individuals in Myanmar
Mutation
94 32381145 The characteristics of pretreatment HIV-1 drug resistance in western Yunnan, China
Mutation
95 32994325 CPSF6-Dependent Targeting of Speckle-Associated Domains Distinguishes Primate from Nonprimate Lentiviral Integration
Mutation
96 33143751 Predictors of first-line antiretroviral therapy failure among adults and adolescents living with HIV/AIDS in a large prevention and treatment program in Nigeria
Mutation
97 33692637 First-Line Antiretroviral Regimen Failure and Determinants in an Urban HIV Clinic at Phramongkutklao Hospital, Bangkok, Thailand: 20 Years Experience
Mutation
98 40106654 Mutations associated with viral resistance to integrase in individuals initiating dolutegravir-containing antiretroviral therapy: retrospective cohort, Brazil 2017-2019
Mutation
99 40146807 Cabotegravir/rilpivirine resistance in a patient living with HIV despite on-time administration: A case report
Mutation
100 18582198 Nevirapine resistance in women and infants after first versus repeated use of single-dose nevirapine for prevention of HIV-1 vertical transmission
Mutation
101 18614915 Optimization of the oligonucleotide ligation assay, a rapid and inexpensive test for detection of HIV-1 drug resistance mutations, for non-North American variants
Mutation
102 18638397 Impaired nuclear import and viral incorporation of Vpr derived from a HIV long-term non-progressor
Mutation
103 18645515 Viral dynamics and in vivo fitness of HIV-1 in the presence and absence of enfuvirtide
Mutation
104 18645523 In vitro characterization of multidrug-resistant HIV-1 isolates from a recently infected patient associated with dual tropism and rapid disease progression
Mutation
105 18666824 Minority HIV-1 drug resistance mutations are present in antiretroviral treatment-naive populations and associate with reduced treatment efficacy
Mutation
106 18673537 HLA-C increases HIV-1 infectivity and is associated with gp120
Mutation
107 18684096 Analysis of nevirapine (NVP) resistance in Ugandan infants who were HIV infected despite receiving single-Dose (SD) NVP versus SD NVP plus daily NVP up to 6 weeks of age to prevent HIV vertical transmission
Mutation
108 18687142 Natural variation of HIV-1 group M integrase: implications for a new class of antiretroviral inhibitors
Mutation
109 18992847 Distinct resistance mutation and polymorphism acquisition in HIV-1 protease of subtypes B and F1 from children and adult patients under virological failure
Mutation
110 19005273 Silent mutations are selected in HIV-1 reverse transcriptase and affect enzymatic efficiency
Mutation
111 19005274 Transmission networks of drug resistance acquired in primary/early stage HIV infection
Mutation
112 19918107 Progress in basic and clinical research on HIV resistance: report on the XVIII International HIV Drug Resistance Workshop
Mutation
113 20030841 Treatment outcomes and plasma level of ritonavir-boosted lopinavir monotherapy among HIV-infected patients who had NRTI and NNRTI failure
Mutation
114 20158398 Efficacy and safety of 1-month postpartum zidovudine-didanosine to prevent HIV-resistance mutations after intrapartum single-dose nevirapine
Mutation
115 20174661 HIV drug resistance surveillance using pooled pyrosequencing
Mutation
116 20436677 The HIV-1 integrase mutations Y143C/R are an alternative pathway for resistance to Raltegravir and impact the enzyme functions
Mutation
117 20453629 Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa
Mutation
118 20494390 Subtype-specific conservation of isoleucine 309 in the envelope V3 domain is linked to immune evasion in subtype C HIV-1 infection
Mutation
119 20516563 Clonal resistance analyses of HIV type-1 after failure of therapy with didanosine, lamivudine and tenofovir
Mutation
120 20532178 Prevalence and clinical significance of HIV drug resistance mutations by ultra-deep sequencing in antiretroviral-naive subjects in the CASTLE study
Mutation
121 20578491 Virologic and immunologic outcomes in HIV-infected Cambodian children after 18 months of highly active antiretroviral therapy (HAART)
Mutation
122 21487249 Analysis of nevirapine resistance in HIV-infected infants who received extended nevirapine or nevirapine/zidovudine prophylaxis
Mutation
123 21516199 Suboptimal adherence associated with virological failure and resistance mutations to first-line highly active antiretroviral therapy (HAART) in Bangalore, India
Mutation
124 21569325 The evolution of HIV-1 reverse transcriptase in route to acquisition of Q151M multi-drug resistance is complex and involves mutations in multiple domains
Mutation
125 21655245 Emergence and persistence of minor drug-resistant HIV-1 variants in Ugandan women after nevirapine single-dose prophylaxis
Mutation
126 21663632 High prevalence of HIV-1 drug resistance among patients on first-line antiretroviral treatment in Lome, Togo
Mutation
127 21694608 Genotypic resistance at viral rebound among patients who received lopinavir/ritonavir-based or efavirenz-based first antiretroviral therapy in South Africa
Mutation
128 21754996 Reappearance of minority K103N HIV-1 variants after interruption of ART initiated during primary HIV-1 infection
Mutation
129 21927716 Drug resistance patterns and virus re-suppression among HIV-1 subtype C infected patients receiving non-nucleoside reverse transcriptase inhibitors in South Africa
Mutation
130 22110581 Can linear regression modeling help clinicians in the interpretation of genotypic resistance data? An application to derive a lopinavir-score
Mutation
131 22132100 Resistance patterns selected by nevirapine vs. efavirenz in HIV-infected patients failing first-line antiretroviral treatment: a bayesian analysis
Mutation
132 22293461 Low rates of nucleoside reverse transcriptase inhibitor resistance in a well-monitored cohort in South Africa on antiretroviral therapy
Mutation
133 22448246 Low prevalence of transmitted drug resistance in patients newly diagnosed with HIV-1 infection in Sweden 2003-2010
Mutation
134 22877156 Clinical, epidemiological and molecular features of the HIV-1 subtype C and recombinant forms that are circulating in the city of Sao Paulo, Brazil
Mutation
135 23144802 Screening for and verification of novel mutations associated with drug resistance in the HIV type 1 subtype B(') in China
Mutation
136 24465210 Preservation of tetherin and CD4 counter-activities in circulating Vpu alleles despite extensive sequence variation within HIV-1 infected individuals
Mutation
137 24465566 Molecular and genetic characterization of natural HIV-1 Tat Exon-1 variants from North India and their functional implications
Mutation
138 24586665 Characteristics of HIV-1 natural drug resistance-associated mutations in former paid blood donors in Henan Province, China
Mutation
139 24616600 Characterization of Gp41 polymorphisms in the fusion peptide domain and T-20 (Enfuvirtide) resistance-associated regions in Korean HIV-1 isolates
Mutation
140 25003939 HIV-1 pol diversity among female bar and hotel workers in Northern Tanzania
Mutation
141 25170621 Functional analyses reveal extensive RRE plasticity in primary HIV-1 sequences selected under selective pressure
Mutation
142 25253273 HIV-1 Gag C-terminal amino acid substitutions emerging under selective pressure of protease inhibitors in patient populations infected with different HIV-1 subtypes
Mutation
143 25259833 A uniquely prevalent nonnucleoside reverse transcriptase inhibitor resistance mutation in Russian subtype A HIV-1 viruses
Mutation
144 25303690 Evaluation of dried blood spots collected on filter papers from three manufacturers stored at ambient temperature for application in HIV-1 drug resistance monitoring
Mutation
145 25314293 Development and customization of a color-coded microbeads-based assay for drug resistance in HIV-1 reverse transcriptase
Mutation
146 25397436 Using dried blood spots collected under field condition to determine HIV-1 diversity and drug resistance mutations in resource limited Tanzania
Mutation
147 25397483 HIV-1 group O integrase displays lower susceptibility to raltegravir and has a different mutational pathway for resistance than HIV-1 group M
Mutation
148 25397490 Viral escape in the CNS with multidrug-resistant HIV-1
Mutation
149 25397495 Transmitted antiretroviral drug resistance mutations in newly diagnosed HIV-1 positive patients in Turkey
Mutation
150 25487529 HIV type 1 drug resistance patterns among patients failing first and second line antiretroviral therapy in Nairobi, Kenya
Mutation
151 26020400 Genetic Characteristics of CRF01_AE Among Newly Diagnosed HIV-1-Infected 16- to 25-Year Olds in 3 Geographic Regions of Guangxi, China
Mutation
152 26537685 Structural Insights into HIV-1 Vif-APOBEC3F Interaction
Mutation
153 27039930 Binding of Clinical Inhibitors to a Model Precursor of a Rationally Selected Multidrug Resistant HIV-1 Protease Is Significantly Weaker Than That to the Released Mature Enzyme
Mutation
154 27076106 HIV virological failure and drug resistance in a cohort of Tanzanian HIV-infected adults
Mutation
155 27090171 Identification and Characterization of BMS-955176, a Second-Generation HIV-1 Maturation Inhibitor with Improved Potency, Antiviral Spectrum, and Gag Polymorphic Coverage
Mutation
156 27107820 HIV-1 capsid is involved in post-nuclear entry steps
Mutation
157 27125365 Integrase Strand Transfer Inhibitors (INSTIs) Resistance Mutations in HIV-1 Infected Turkish Patients
Mutation
158 27177767 Usefulness of Integrase resistance testing in proviral HIV-1 DNA in patients with Raltegravir prior failure
Mutation
159 27338425 Viral Suppression and Resistance in a Cohort of Perinatally-HIV Infected (PHIV+) Pregnant Women
Mutation
160 27343732 HIV-1 Vpr increases Env expression by preventing Env from endoplasmic reticulum-associated protein degradation (ERAD)
Mutation
161 27353350 HIV Drug Resistance in Antiretroviral-Naive Patients in Mexico After 10 Years: Is There a Difference?
Mutation
162 27355626 Surveillance of HIV Transmitted Drug Resistance in Latin America and the Caribbean: A Systematic Review and Meta-Analysis
Mutation
163 27367488 The M184I/V and K65R nucleoside resistance mutations in HIV-1 prevent the emergence of resistance mutations against dolutegravir
Mutation
164 27704010 Human Immunodeficiency Virus-1 Sequence Changes and Drug Resistance Mutation Among Virologic Failures of Lopinavir/Ritonavir Monotherapy: AIDS Clinical Trials Group Protocol A5230
Mutation
165 27736898 HIV Drug Resistance in Antiretroviral Treatment-Naive Individuals in the Largest Public Hospital in Nicaragua, 2011-2015
Mutation
166 27858889 Correlates of infection and molecular characterization of blood-borne HIV, HCV, and HBV infections in HIV-1 infected inmates in Italy: An observational cross-sectional study
Mutation
167 27992602 Receptor Activation of HIV-1 Env Leads to Asymmetric Exposure of the gp41 Trimer
Mutation
168 27997554 Drug Resistance and Virological Failure among HIV-Infected Patients after a Decade of Antiretroviral Treatment Expansion in Eight Provinces of China
Mutation
169 28107423 Characterization of the Drug Resistance Profiles of Patients Infected with CRF07_BC Using Phenotypic Assay and Ultra-Deep Pyrosequencing
Mutation
170 28149058 Effect of HIV-1 Subtype C integrase mutations implied using molecular modeling and docking data
Mutation
171 28153748 A DEAD-Box Helicase Mediates an RNA Structural Transition in the HIV-1 Rev Response Element
Mutation
172 28159573 Factors Associated With the Control of Viral Replication and Virologic Breakthrough in a Recently Infected HIV-1 Controller
Mutation
173 28167814 Prevalence of Transmitted Drug-Resistance Mutations and Polymorphisms in HIV-1 Reverse Transcriptase, Protease, and gp41 Sequences Among Recent Seroconverters in Southern Poland
Mutation
174 28212411 Lack of impact of pre-existing T97A HIV-1 integrase mutation on integrase strand transfer inhibitor resistance and treatment outcome
Mutation
175 28301548 HIV-1 genetic diversity and antiretroviral drug resistance among individuals from Roraima state, northern Brazil
Mutation
176 28302150 Identification of a tripartite interaction between the N-terminus of HIV-1 Vif and CBFbeta that is critical for Vif function
Mutation
177 28589513 Prevalence of HIV-1 transmitted drug resistance in recently infected, treatment-naive persons in the Southwest of Iran, 2014-2015
Mutation
178 28604824 Decline in CD4 T lymphocytes with monotherapy bridging strategy for non-adherent adolescents living with HIV infection: Results of the IMPAACT P1094 randomized trial
Mutation
179 28622345 The infection staging and profile of genotypic distribution and drug resistance mutation among the human immunodeficiency virus-1 infected blood donors from five Chinese blood centers, 2012-2014
Mutation
180 28679441 HIV-1 genetic diversity and primary drug resistance mutations before large-scale access to antiretroviral therapy, Republic of Congo
Mutation
181 28750025 HIV drug resistance in HIV positive individuals under antiretroviral treatment in Shandong Province, China
Mutation
182 28797181 HIV Resistance and Prevention of Mother-to-Child Transmission Regimen in HIV-Infected Infants in Northern Tanzania
Mutation
183 29222332 Stabilization of the gp120 V3 loop through hydrophobic interactions reduces the immunodominant V3-directed non-neutralizing response to HIV-1 envelope trimers
Mutation
184 29672607 Infant transmitted/founder HIV-1 viruses from peripartum transmission are neutralization resistant to paired maternal plasma
Mutation
185 29683855 A week-48 randomized phase-3 trial of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naive HIV-1 patients
Mutation
186 29683856 Seroconversion on preexposure prophylaxis: a case report with segmental hair analysis for timed adherence determination
Mutation
187 29684083 HIV-1 transmission networks across Cyprus (2010-2012)
Mutation
188 29732898 Changes from 2000 to 2009 in the Prevalence of HIV-1 Containing Drug Resistance-Associated Mutations from Antiretroviral Therapy-Naive, HIV-1-Infected Patients in the United States
Mutation
189 29739342 High prevalence of HIV-1 transmitted drug resistance among therapy-naive Burmese entering travelers at Dehong ports in Yunnan, China
Mutation
190 29763303 Design and Synthesis of Highly Potent HIV-1 Protease Inhibitors Containing Tricyclic Fused Ring Systems as Novel P2 Ligands: Structure-Activity Studies, Biological and X-ray Structural Analysis
Mutation
191 29769530 Comparison of the genotypic and phenotypic properties of HIV-1 standard subtype B and subtype B/B' env molecular clones derived from infections in China
Mutation
192 29846534 Trends in the Molecular Epidemiology and Genetic Mechanisms of Transmitted Human Immunodeficiency Virus Type 1 Drug Resistance in a Large US Clinic Population
Mutation
193 29856864 Evaluation of different analysis pipelines for the detection of HIV-1 minority resistant variants
Mutation
194 29861843 HIV-1 integrase strand-transfer inhibitor resistance in southern Taiwan
Mutation
195 29870534 Epidemiological surveillance of HIV-1 transmitted drug resistance among newly diagnosed individuals in Shijiazhuang, northern China, 2014-2015
Mutation
196 29884219 Prevalence of resistance to integrase strand-transfer inhibitors (INSTIs) among untreated HIV-1 infected patients in Morocco
Mutation
197 29892199 Patterns of emergent resistance-associated mutations after initiation of non-nucleoside reverse-transcriptase inhibitor-containing antiretroviral regimens in Taiwan: a multicenter cohort study
Mutation
198 29950423 HIV-1 Subtype C-Infected Children with Exceptional Neutralization Breadth Exhibit Polyclonal Responses Targeting Known Epitopes
Mutation
199 29953436 Genotyping performance evaluation of commercially available HIV-1 drug resistance test
Mutation
200 29970102 CD8(+) T cells specific for conserved, cross-reactive Gag epitopes with strong ability to suppress HIV-1 replication
Mutation
201 29975689 HIV-1 diversity among young women in rural South Africa: HPTN 068
Mutation
202 29977795 Detection of minority drug resistant mutations in Malawian HIV-1 subtype C-positive patients initiating and on first-line antiretroviral therapy
Mutation
203 29977967 Impact of the M184V Resistance Mutation on Virological Efficacy and Durability of Lamivudine-Based Dual Antiretroviral Regimens as Maintenance Therapy in Individuals With Suppressed HIV-1 RNA: A Cohort Study
Mutation
204 30016324 HIV-1 infection among crack cocaine users in a region far from the epicenter of the HIV epidemic in Brazil: Prevalence and molecular characteristics
Mutation
205 30040081 Selection analyses of paired HIV-1 gag and gp41 sequences obtained before and after antiretroviral therapy
Mutation
206 30046244 Higher Frequency of HIV-1 Drug Resistance and Increased Nucleoside Reverse Transcriptase Inhibitor Mutations among the HIV-1 Positive Antiretroviral Therapy-Naive patients Coinfected With Mycobacterium tuberculosis Compared With Only HIV Infection in India
Mutation
207 30048246 Extensive host immune adaptation in a concentrated North American HIV epidemic
Mutation
208 30056211 Binding of host factors to stabilized HIV-1 capsid tubes
Mutation
209 30079168 Human immunodeficiency virus type 1 drug resistance in a subset of mothers and their infants receiving antiretroviral treatment in Ouagadougou, Burkina Faso
Mutation
210 30115986 Prevalence of Transmitted HIV drug resistance in antiretroviral treatment naive newly diagnosed individuals in China
Mutation
211 30119633 Selective resistance profiles emerging in patient-derived clinical isolates with cabotegravir, bictegravir, dolutegravir, and elvitegravir
Mutation
212 30122963 HIV-1 genotypic drug resistance in patients with virological failure to single-tablet antiretroviral regimens in southern Taiwan
Mutation
213 30134290 HIV-1 second-line failure and drug resistance at high-level and low-level viremia in Western Kenya
Mutation
214 30148406 Prevalence of Darunavir Resistance in the United States from 2010 to 2017
Mutation
215 30151407 Prevalence and Transmission Dynamics of HIV-1 Transmitted Drug Resistance in a Southeastern Cohort
Mutation
216 30174310 The High Genetic Barrier of EFdA/MK-8591 Stems from Strong Interactions with the Active Site of Drug-Resistant HIV-1 Reverse Transcriptase
Mutation
217 30201008 Next-generation sequencing analyses of the emergence and maintenance of mutations in CTL epitopes in HIV controllers with differential viremia control
Mutation
218 30223845 Emergence of HIV-1 drug resistance mutations in mothers on treatment with a history of prophylaxis in Ghana
Mutation
219 30249546 Impact of a single HLA-A*24:02-associated escape mutation on the detrimental effect of HLA-B*35:01 in HIV-1 control
Mutation
220 30277466 A comparison between two dolutegravir-based two-drug regimens as switch strategies in a multicentre cohort of HIV-1-infected patients
Mutation
221 30286160 HIV-1C proviral DNA for detection of drug resistance mutations
Mutation
222 30304061 HIV-genetic diversity and drug resistance transmission clusters in Gondar, Northern Ethiopia, 2003-2013
Mutation
223 30305383 Limited Marginal Utility of Deep Sequencing for HIV Drug Resistance Testing in the Age of Integrase Inhibitors
Mutation
224 30309385 Surveillance of transmitted HIV-1 antiretroviral drug resistance in the context of decentralized HIV care in Senegal and the Ebola outbreak in Guinea
Mutation
225 30314470 Virologic suppression in response to antiretroviral therapy despite extensive resistance within HIV-1 reverse transcriptase after the first virologic failure
Mutation
226 30315192 Antiretroviral resistance, genotypic characterization and origin of Human Immunodeficiency Virus among the infected wives of Intravenous drug users in Manipur
Mutation
227 30325775 Sexual intermingling of Arab and Jewish MSM in Israel: results of a molecular epidemiology study
Mutation
228 30352054 Safety, efficacy, and dose response of the maturation inhibitor GSK3532795 (formerly known as BMS-955176) plus tenofovir/emtricitabine once daily in treatment-naive HIV-1-infected adults: Week 24 primary analysis from a randomized Phase IIb trial
Mutation
229 30356083 Genetic divergence of HIV-1 B subtype in Italy over the years 2003-2016 and impact on CTL escape prevalence
Mutation
230 30364958 Compromise of Second-Line Antiretroviral Therapy Due to High Rates of Human Immunodeficiency Virus Drug Resistance in Mozambican Treatment-Experienced Children With Virologic Failure
Mutation
231 30379960 Prevalence of HIV-1 pretreatment drug resistance among treatment naive pregnant women in Bissau, Guinea Bissau
Mutation
232 30401010 Characterisation of HIV-1 transmission clusters and drug-resistant mutations in Denmark, 2004 to 2016
Mutation
233 30408827 Increasing proportions of HIV-1 non-B subtypes and of NNRTI resistance between 2013 and 2016 in Germany: Results from the national molecular surveillance of new HIV-diagnoses
Mutation
234 30409215 Characterization of minority HIV-1 drug resistant variants in the United Kingdom following the verification of a deep sequencing-based HIV-1 genotyping and tropism assay
Mutation
235 30461149 Prevalence and determinants of resistance mutations in HIV-1-infected patients exposed to integrase inhibitors in a large Italian cohort
Mutation
236 30477526 Long-term virological outcome in children receiving first-line antiretroviral therapy
Mutation
237 30503324 Acquisition of tenofovir-susceptible, emtricitabine-resistant HIV despite high adherence to daily pre-exposure prophylaxis: a case report
Mutation
238 30513108 Raltegravir-intensified initial antiretroviral therapy in advanced HIV disease in Africa: A randomised controlled trial
Mutation
239 30538823 Maintenance and reappearance of extremely divergent intra-host HIV-1 variants
Mutation
240 30544247 Virological outcomes of boosted protease inhibitor-based first-line ART in subjects harbouring thymidine analogue-associated mutations as the sole form of transmitted drug resistance
Mutation
241 30562356 HIV-1 subtype diversity, transmission networks and transmitted drug resistance amongst acute and early infected MSM populations from Coastal Kenya
Mutation
242 30568974 Rapid Development of High-Level Resistance to Dolutegravir With Emergence of T97A Mutation in 2 Treatment-Experienced Individuals With Baseline Partial Sensitivity to Dolutegravir
Mutation
243 30568984 Human Immunodeficiency Virus-1 Drug Resistance Patterns Among Adult Patients Failing Second-Line Protease Inhibitor-Containing Regimens in Namibia, 2010-2015
Mutation
244 30577760 Rates of HBV, HCV, HDV and HIV type 1 among pregnant women and HIV type 1 drug resistance-associated mutations in breastfeeding women on antiretroviral therapy
Mutation
245 30596682 First evaluation of the Next-Generation Sequencing platform for the detection of HIV-1 drug resistance mutations in Belgium
Mutation
246 30621727 Drug resistance evolution in patients with human immunodeficiency virus-1 under long-term antiretroviral treatment-failure in Yunnan Province, China
Mutation
247 30640198 High Levels of HIV-1 Drug Resistance in Children Who Acquired HIV Infection Through Mother to Child Transmission in the Era of Option B+, Haiti, 2013 to 2014
Mutation
248 30648124 Development of the R263K Mutation to Dolutegravir in an HIV-1 Subtype D Virus Harboring 3 Class-Drug Resistance
Mutation
249 30650070 CD4 occupancy triggers sequential pre-fusion conformational states of the HIV-1 envelope trimer with relevance for broadly neutralizing antibody activity
Mutation
250 30650082 Prevalence and persistence of transmitted drug resistance mutations in the German HIV-1 Seroconverter Study Cohort
Mutation
251 30714528 Molecular Antiretroviral Resistance Markers of Human Immunodeficiency Virus-1 of CRF01_AE Subtype in Bali, Indonesia
Mutation
252 30717826 HIV-1 Vpu is a potent transcriptional suppressor of NF-kappaB-elicited antiviral immune responses
Mutation
253 30732150 Drug resistance mutations and viral load in human immunodeficiency virus type 2 and dual HIV-1/HIV-2 infected patients in Ghana
Mutation
254 30759103 Presence, persistence and effects of pre-treatment HIV-1 drug resistance variants detected using next generation sequencing: A Retrospective longitudinal study from rural coastal Kenya
Mutation
255 30798695 HIV Viral Dynamics of Lopinavir/Ritonavir Monotherapy as Second-Line Treatment: A Prospective, Single-Arm Trial
Mutation
256 30871487 HIV-1 drug resistance testing is essential for heavily-treated patients switching from first- to second-line regimens in resource-limited settings: evidence from routine clinical practice in Cameroon
Mutation
257 30891603 High predictive efficacy of integrase strand transfer inhibitors in perinatally HIV-1-infected African children in therapeutic failure of first- and second-line antiretroviral drug regimens recommended by the WHO
Mutation
258 30894467 Two Coselected Distal Mutations in HIV-1 Reverse Transcriptase (RT) Alter Susceptibility to Nonnucleoside RT Inhibitors and Nucleoside Analogs
Mutation
259 30906285 A 28-Year History of HIV-1 Drug Resistance and Transmission in Washington, DC
Mutation
260 30937190 Primary HIV Drug Resistance among Recently Infected Cases of HIV in North-West India
Mutation
261 30951600 Long-Term Safety and Efficacy of Dolutegravir in Treatment-Experienced Adolescents With Human Immunodeficiency Virus Infection: Results of the IMPAACT P1093 Study
Mutation
262 30961560 Diversity of HIV-1 genotypes and high prevalence of pretreatment drug resistance in newly diagnosed HIV-infected patients in Shanghai, China
Mutation
263 30964884 Validation of publicly-available software used in analyzing NGS data for HIV-1 drug resistance mutations and transmission networks in a Washington, DC, Cohort
Mutation
264 30989237 Prevalence of drug resistance mutations among ART-naive and -experienced HIV-infected patients in Sierra Leone
Mutation
265 31010245 Humoral Response to the HIV-1 Envelope V2 Region in a Thai Early Acute Infection Cohort
Mutation
266 31024744 Consensus Integrase of a New HIV-1 Genetic Variant CRF63_02A1
Mutation
267 31037930 Resistance to HIV integrase strand transfer inhibitors in Argentina: first interim survey
Mutation
268 31126879 Broad and Potent Neutralizing Antibodies Recognize the Silent Face of the HIV Envelope
Mutation
269 31143232 HIV drug resistance among naive HIV-infected patients in Iran
Mutation
270 31143879 Trends in Pretreatment HIV-1 Drug Resistance in Antiretroviral Therapy-naive Adults in South Africa, 2000-2016: A Pooled Sequence Analysis
Mutation
271 31172041 Highly Drug-Resistant HIV-1 Protease Mutant PRS17 Shows Enhanced Binding to Substrate Analogues
Mutation
272 31178836 Characteristics of Envelope Genes in a Chinese Chronically HIV-1 Infected Patient With Broadly Neutralizing Activity
Mutation
273 31228958 Two-year cross-sectional studies reveal that single, young MSMs in Shenzhen, China are at high risk for HIV infection
Mutation
274 31234536 In Silico Insights into HIV-1 Vpu-Tetherin Interactions and Its Mutational Counterparts
Mutation
275 31257432 Rates of HIV-1 virological suppression and patterns of acquired drug resistance among fisherfolk on first-line antiretroviral therapy in Uganda
Mutation
276 31262272 A viral genome wide association study and genotypic resistance testing in patients failing first line antiretroviral therapy in the first large countrywide Ethiopian HIV cohort
Mutation
277 31266818 Sustained virological response and drug resistance among female sex workers living with HIV on antiretroviral therapy in Kampala, Uganda: a cross-sectional study
Mutation
278 31269034 Drug resistance from preferred antiretroviral regimens for HIV infection in South Africa: A modeling study
Mutation
279 31330378 Evaluation of HIV-1 integrase resistance emergence and evolution in patients treated with integrase inhibitors
Mutation
280 31353798 Near full genome characterization of HIV-1 unique recombinant forms in Cameroon reveals dominant CRF02_AG and F2 recombination patterns
Mutation
281 31416460 Human immunodeficiency virus type 1 ((HIV-1) subtypes in the northwest region, Cameroon
Mutation
282 31430369 Switching to bictegravir/emtricitabine/tenofovir alafenamide maintained HIV-1 RNA suppression in participants with archived antiretroviral resistance including M184V/I
Mutation
283 31432614 Lack of effectiveness of adherence counselling in reversing virological failure among patients on long-term antiretroviral therapy in rural Uganda
Mutation
284 31443633 Trend of HIV transmitted drug resistance before and after implementation of HAART regimen restriction in the treatment of HIV-1 infected patients in southern Taiwan
Mutation
285 31479466 National survey of pre-treatment HIV drug resistance in Cuban patients
Mutation
286 31504041 Identification of variant HIV envelope proteins with enhanced affinities for precursors to anti-gp41 broadly neutralizing antibodies
Mutation
287 31516033 Week 48 Resistance Analyses of the Once-Daily, Single-Tablet Regimen Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) in Adults Living with HIV-1 from the Phase III Randomized AMBER and EMERALD Trials
Mutation
288 31518723 Transmitted drug resistance mutations and trends of HIV-1 subtypes in treatment-naive patients: A single-centre experience
Mutation
289 31535044 Surveillance of transmitted HIV drug resistance among newly diagnosed, treatment-naive individuals at a county HIV clinic in Santa Clara County
Mutation
290 31551948 Raltegravir-Induced Adaptations of the HIV-1 Integrase: Analysis of Structure, Variability, and Mutation Co-occurrence
Mutation
291 31552748 Mexican HIV-1 Protease Sequence Diversity
Mutation
292 31555932 Rapid Identification and Investigation of an HIV Risk Network Among People Who Inject Drugs -Miami, FL, 2018
Mutation
293 31591964 Epistasis and entrenchment of drug resistance in HIV-1 subtype B
Mutation
294 31617907 Integrase strand transfer inhibitor (INSTI)-resistance mutations for the surveillance of transmitted HIV-1 drug resistance
Mutation
295 31622432 Resistance profile of the HIV-1 maturation inhibitor GSK3532795 in vitro and in a clinical study
Mutation
296 31640718 Characterization of resistance to a potent D-peptide HIV entry inhibitor
Mutation
297 31651864 HIV-1 subtype diversity, drug resistance, and genetic transmission networks in men who have sex with men with virologic failure in antiretroviral therapy in Sichuan, China, 2011 to 2017
Mutation
298 31660328 Impact of the M184V/I Mutation on the Efficacy of Abacavir/Lamivudine/Dolutegravir Therapy in HIV Treatment-Experienced Patients
Mutation
299 31665623 HIV-1 Vif Triggers Cell Cycle Arrest by Degrading Cellular PPP2R5 Phospho-regulators
Mutation
300 31678241 Natural presence of V179E and rising prevalence of E138G in HIV-1 reverse transcriptase in CRF55_01B viruses
Mutation
301 31683782 HIV-1 Envelope Glycoprotein Amino Acids Signatures Associated with Clade B Transmitted/Founder and Recent Viruses
Mutation
302 31690677 Analysis of CA Content and CPSF6 Dependence of Early HIV-1 Replication Complexes in SupT1-R5 Cells
Mutation
303 31693887 Natural HIV-1 Nef Polymorphisms Impair SERINC5 Downregulation Activity
Mutation
304 31735575 Fragment hopping-based discovery of novel sulfinylacetamide-diarylpyrimidines (DAPYs) as HIV-1 nonnucleoside reverse transcriptase inhibitors
Mutation
305 31736889 HIV-1 Nef Targets HDAC6 to Assure Viral Production and Virus Infection
Mutation
306 31741096 HIV-1 integrase drug-resistance mutations in Iranian treatment-experienced HIV-1-infected patients
Mutation
307 31745412 HIV Drug Resistance among Patients Failing Therapy at a Tertiary Center in Oman: A Case Record Review
Mutation
308 31751428 Genetic diversity and antiretroviral resistance-associated mutation profile of treated and naive HIV-1 infected patients from the Northwest and Southwest regions of Cameroon
Mutation
309 31754119 Analysis of HIV-1 diversity, primary drug resistance and transmission networks in Croatia
Mutation
310 31761656 Heterocycle amide isosteres: An approach to overcoming resistance for HIV-1 integrase strand transfer inhibitors
Mutation
311 31764077 Genotypic resistance profiles of HIV-2-infected patients from Cape Verde failing first-line antiretroviral therapy
Mutation
312 31764198 Long-acting implants to treat and prevent HIV infection
Mutation
313 31770425 Genetic diversity and drug resistance of HIV-1 among infected pregnant women newly diagnosed in Luanda, Angola
Mutation
314 31773888 HIV pretreatment drug resistance among cisgender MSM and transgender women from Lima, Peru
Mutation
315 31774913 Human Immunodeficiency Virus-1 Viral Load Is Elevated in Individuals With Reverse-Transcriptase Mutation M184V/I During Virological Failure of First-Line Antiretroviral Therapy and Is Associated With Compensatory Mutation L74I
Mutation
316 31776272 HIV-1 Accessory Protein Vpr Interacts with REAF/RPRD2 To Mitigate Its Antiviral Activity
Mutation
317 31776582 Sensitive Drug-Resistance Assays Reveal Long-Term Persistence of HIV-1 Variants with the K103N Nevirapine (NVP) Resistance Mutation in Some Women and Infants after the Administration of Single-Dose NVP: HIVNET 012
Mutation
318 31781759 Engagement in Care, Viral Suppression, Drug Resistance, and Reasons for Nonengagement After Home-Based Same-Day Antiretroviral Therapy Initiation in Lesotho: A Two-Year Follow-up of the CASCADE Trial
Mutation
319 31796053 Mutations of Glu560 within HIV-1 Envelope Glycoprotein N-terminal heptad repeat region contribute to resistance to peptide inhibitors of virus entry
Mutation
320 31801029 A case of M184V mutant human immunodeficiency virus in a patient using daily pre-exposure prophylaxis
Mutation
321 31818716 Evaluation of the management of pretreatment HIV drug resistance by oligonucleotide ligation assay: a randomised controlled trial
Mutation
322 31819984 Pretreatment HIV drug resistance spread within transmission clusters in Mexico City
Mutation
323 31830799 HIV-1 Integrase Diversity and Resistance-Associated Mutations and Polymorphisms Among Integrase Strand Transfer Inhibitor-Naive HIV-1 Patients from Cameroon
Mutation
324 31833849 Week 96 results of a phase 3 trial of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naive HIV-1 patients
Mutation
325 31872074 Elucidating molecular interactions of L-nucleotides with HIV-1 reverse transcriptase and mechanism of M184V-caused drug resistance
Mutation
326 31878069 Prevalence of Non-B HIV-1 Subtypes in North Italy and Analysis of Transmission Clusters Based on Sequence Data Analysis
Mutation
327 31879782 Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in a Rapid-Initiation Model of Care for Human Immunodeficiency Virus Type 1 Infection: Primary Analysis of the DIAMOND Study
Mutation
328 31885806 HIV-1 Reverse Transcriptase Promotes Tumor Growth and Metastasis Formation via ROS-Dependent Upregulation of Twist
Mutation
329 31889319 Analyses of HIV-1 integrase gene sequences among treatment-naive patients in the Eastern Cape, South Africa
Mutation
330 31905383 Efficacy and Safety of Switching to Dolutegravir/Lamivudine Fixed-Dose 2-Drug Regimen vs Continuing a Tenofovir Alafenamide-Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Phase 3, Randomized, Noninferiority TANGO Study
Mutation
331 31906562 HIV-1 Mutant Assembly, Processing and Infectivity Expresses Pol Independent of Gag
Mutation
332 31914782 Prevalence of HIV-1 Drug-Resistance Genotypes Among Unique Recombinant Forms from Yunnan Province, China in 2016-2017
Mutation
333 31915714 Clinical Outcomes Following the Use of Archived Proviral HIV-1 DNA Genotype to Guide Antiretroviral Therapy Adjustment
Mutation
334 31915716 Antiretroviral Treatment Simplification With 2-Drug Regimens: Impact of Transmitted Drug Resistance Mutations
Mutation
335 31922120 Determining virological suppression and resuppression by point-of-care viral load testing in a HIV care setting in sub-Saharan Africa
Mutation
336 31923334 Altered-specificity mutants of the HIV Rev arginine-rich motif-RRE IIB interaction
Mutation
337 31926287 Retrospective study on the outcome of two-drug regimens based on dolutegravir plus one reverse transcriptase inhibitor in virologically-suppressed HIV-infected patients
Mutation
338 31927793 Continuation of emtricitabine/lamivudine within combination antiretroviral therapy following detection of the M184V/I HIV-1 resistance mutation
Mutation
339 31929566 High failure rates of protease inhibitor-based antiretroviral treatment in rural Tanzania - A prospective cohort study
Mutation
340 31941344 The 4th and 112th Residues of Viral Capsid Cooperatively Modulate Capsid-CPSF6 Interactions of HIV-1
Mutation
341 31943114 Binding interface and impact on protease cleavage for an RNA aptamer to HIV-1 reverse transcriptase
Mutation
342 31956856 Pre-treatment HIV-drug resistance associated with virologic outcome of first-line NNRTI-antiretroviral therapy: A cohort study in Kenya
Mutation
343 31959116 Low levels of HIV-1 drug resistance mutations in patients who achieved viral re-suppression without regimen switch: a retrospective study
Mutation
344 31965175 Expanded Spectrum of Antiretroviral-Selected Mutations in Human Immunodeficiency Virus Type 2
Mutation
345 31976534 Prevalence of doravirine-associated resistance mutations in HIV-1-infected antiretroviral-experienced patients from two large databases in France and Italy
Mutation
346 31982483 Failure to bictegravir and development of resistance mutations in an antiretroviral-experienced patient
Mutation
347 31988104 Antiviral Activity of Tenofovir Alafenamide against HIV-1 with Thymidine Analog-Associated Mutations and M184V
Mutation
348 31993580 Following the path: Increasing trends of HIV-1 drug resistance in China
Mutation
349 32004936 Discovery, synthesis, and optimization of an N-alkoxy indolylacetamide against HIV-1 carrying NNRTI-resistant mutations from the Isatis indigotica root
Mutation
350 32005262 Comparison of HIV drug resistance profiles across HIV-1 subtypes A and D for patients receiving a tenofovir-based and zidovudine-based first line regimens in Uganda
Mutation
351 32006797 Pharmacophore-fusing design of pyrimidine sulfonylacetanilides as potent non-nucleoside inhibitors of HIV-1 reverse transcriptase
Mutation
352 32014042 Genetic characterization of HIV-1 epidemic in Anhui Province, China
Mutation
353 32025714 Prevalence of viral load suppression, predictors of virological failure and patterns of HIV drug resistance after 12 and 48 months on first-line antiretroviral therapy: a national cross-sectional survey in Uganda
Mutation
354 32029767 A cross-sectional study to characterize local HIV-1 dynamics in Washington, DC using next-generation sequencing
Mutation
355 32030406 The algorithm used for the interpretation of doravirine transmitted drug resistance strongly influences clinical practice and guideline recommendations
Mutation
356 32041622 HIV-1 acquired drug resistance to integrase inhibitors in a cohort of antiretroviral therapy multi-experienced Mexican patients failing to raltegravir: a cross-sectional study
Mutation
357 32045455 HIV-1 subtypes and drug resistance mutations among female sex workers varied in different cities and regions of the Democratic Republic of Congo
Mutation
358 32046664 The S68G polymorphism is a compensatory mutation associated with the drug resistance mutation K65R in CRF01_AE strains
Mutation
359 32049783 High resistance to reverse transcriptase inhibitors among persons infected with human immunodeficiency virus type 1 subtype circulating recombinant form 02_AG in Ghana and on antiretroviral therapy
Mutation
360 32053707 HIV protease cleaves the antiviral m6A reader protein YTHDF3 in the viral particle
Mutation
361 32057044 Revealing the binding and drug resistance mechanism of amprenavir, indinavir, ritonavir, and nelfinavir complexed with HIV-1 protease due to double mutations G48T/L89M by molecular dynamics simulations and free energy analyses
Mutation
362 32071061 Discordance between Etravirine Phenotype and Genotype-Based Predicted Phenotype for Subtype C HIV-1 from First-Line Antiretroviral Therapy Failures in South Africa
Mutation
363 32081778 High rates of tenofovir failure in a CRF01_AE-predominant HIV epidemic in the Philippines
Mutation
364 32094387 High HIV-1 diversity in immigrants resident in Italy (2008-2017)
Mutation
365 32096745 Analysis of Vpr Genetic Variations between Chinese Major Circulating Recombinants CRF01_AE and CRF07_BC
Mutation
366 32102090 Analysis of unusual and signature APOBEC-mutations in HIV-1 pol next-generation sequences
Mutation
367 32102660 Natural polymorphisms in HIV-1 CRF01_AE strain and profile of acquired drug resistance mutations in a long-term combination treatment cohort in northeastern China
Mutation
368 32105319 High prevalence of integrase mutation L74I in West African HIV-1 subtypes prior to integrase inhibitor treatment
Mutation
369 32106437 Variability in HIV-1 Integrase Gene and 3'-Polypurine Tract Sequences in Cameroon Clinical Isolates, and Implications for Integrase Inhibitors Efficacy
Mutation
370 32106666 Molecular Identification of HIV-1 in the Presence of Hepatitis B Virus and Hepatitis C Virus Co-infections
Mutation
371 32116431 Characterization of HIV-1 Integrase Gene and Resistance Associated Mutations Prior to Roll out of Integrase Inhibitors by Kenyan National HIV-Treatment Program in Kenya
Mutation
372 32119663 Zimbabwe's national third-line antiretroviral therapy program: Cohort description and treatment outcomes
Mutation
373 32119691 HIV-1 reverse transcriptase and protease mutations for drug-resistance detection among treatment-experienced and naive HIV-infected individuals
Mutation
374 32121161 Molecular Epidemiology of HIV-1 Infected Migrants Followed up in Portugal: Trends between 2001-2017
Mutation
375 32125378 Impact of genotypic diversity on selection of subtype-specific drug resistance profiles during raltegravir-based therapy in individuals infected with B and BF recombinant HIV-1 strains
Mutation
376 32126792 Circulating HIV-1 Integrase Genotypes in Tanzania: Implication on the Introduction of Integrase Inhibitors-Based Antiretroviral Therapy Regimen
Mutation
377 32129987 Defective Strand-Displacement DNA Synthesis Due to Accumulation of Thymidine Analogue Resistance Mutations in HIV-2 Reverse Transcriptase
Mutation
378 32138739 HIV drug resistance in patients in China's national HIV treatment programme who have been on first-line ART for at least 9 months
Mutation
379 32141388 Presence of V72I, G123S and R127K Integrase Inhibitor polymorphisms could reduce ART effectiveness: a retrospective longitudinal study
Mutation
380 32154864 Frequency of capsid substitutions associated with GS-6207 in vitro resistance in HIV-1 from antiretroviral-naive and -experienced patients
Mutation
381 32156815 Maternal Broadly Neutralizing Antibodies Can Select for Neutralization-Resistant, Infant-Transmitted/Founder HIV Variants
Mutation
382 32158555 Drug resistance after cessation of efavirenz-based antiretroviral treatment started in pregnancy
Mutation
383 32160290 Identification of gp120 polymorphisms in HIV-1 B subtype potentially associated with resistance to fostemsavir
Mutation
384 32175088 Chorea associated with persistent low-level viremia in a patient living with HIV: a case report
Mutation
385 32179688 Loss of Nef-mediated CD3 down-regulation in the HIV-1 lineage increases viral infectivity and spread
Mutation
386 32183488 2-(Arylamino)-6-(trifluoromethyl)nicotinic Acid Derivatives: New HIV-1 RT Dual Inhibitors Active on Viral Replication
Mutation
387 32183889 Prevalence of acquired drug resistance mutations in antiretroviral- experiencing subjects from 2012 to 2017 in Hunan Province of central South China
Mutation
388 32187548 Cyclophilin A Prevents HIV-1 Restriction in Lymphocytes by Blocking Human TRIM5alpha Binding to the Viral Core
Mutation
389 32197300 Structural and Functional Characterization of the Secondary Mutation N126K Selected by Various HIV-1 Fusion Inhibitors
Mutation
390 32205723 Near point-of-care, point-mutation test to detect drug resistance in HIV-1: a validation study in a Mexican cohort
Mutation
391 32214358 Characterization of subtypes and transmitted drug resistance strains of HIV among Beijing residents between 2001-2016
Mutation
392 32216752 The role of drug resistance in poor viral suppression in rural South Africa: findings from a population-based study
Mutation
393 32235557 Scaffold Hopping in Discovery of HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors: From CH(CN)-DABOs to CH(CN)-DAPYs
Mutation
394 32259255 Characterization of viral rebounds on dual etravirine/raltegravir maintenance therapy (ANRS-163 ETRAL trial)
Mutation
395 32264923 Multidrug-resistant HIV viral rebound during early syphilis: a case report
Mutation
396 32265875 Drug Resistance Mutations Against Protease, Reverse Transcriptase and Integrase Inhibitors in People Living With HIV-1 Receiving Boosted Protease Inhibitors in South Africa
Mutation
397 32266208 In silico Design of Novel HIV-1 NNRTIs Based on Combined Modeling Studies of Dihydrofuro[3,4-d]pyrimidines
Mutation
398 32267205 Efficacy and safety of lower dose tenofovir disoproxil fumarate and efavirenz versus standard dose in HIV-infected, antiretroviral-naive adults: a multicentre, randomized, noninferiority trial
Mutation
399 32267869 Polymorphisms and drug resistance analysis of HIV-1 isolates from patients on first line antiretroviral therapy (ART) in South-eastern Nigeria
Mutation
400 32279138 Characterization of HIV-1 subtypes and drug resistance mutations in Henan Province, China (2017-2019)
Mutation
401 32282853 TRIM34 restricts HIV-1 and SIV capsids in a TRIM5alpha-dependent manner
Mutation
402 32294040 Genetic Diversity and Drug Resistance of HIV-1 CRF55_01B in Guangdong, China
Mutation
403 32300784 Characteristics of drug resistance in HIV-1 CRF55_01B from ART-experienced patients in Guangdong, China
Mutation
404 32309558 The role of mutations at codons 32, 47, 54, and 90 in HIV-1 protease flap dynamics
Mutation
405 32321820 Impact of HLA-B*52:01-Driven Escape Mutations on Viral Replicative Capacity
Mutation
406 32331438 HIV-1 Sub-Subtype A6: Settings for Normalised Identification and Molecular Epidemiology in the Southern Federal District, Russia
Mutation
407 32345262 Natural presence of the V179D and K103R/V179D mutations associated with resistance to nonnucleoside reverse transcriptase inhibitors in HIV-1 CRF65_cpx strains
Mutation
408 32371875 HIV-1 molecular epidemiology and drug resistance-associated mutations among treatment-naive blood donors in China
Mutation
409 32379830 Molecular dynamic simulations to investigate the structural impact of known drug resistance mutations on HIV-1C Integrase-Dolutegravir binding
Mutation
410 32389483 Design, synthesis and SAR study of bridged tricyclic pyrimidinone carboxamides as HIV-1 integrase inhibitors
Mutation
411 32392227 Gp41-targeted antibodies restore infectivity of a fusion-deficient HIV-1 envelope glycoprotein
Mutation
412 32408111 Dolutegravir plus lamivudine for maintenance of HIV viral suppression in adults with and without historical resistance to lamivudine: 48-week results of a non-randomized, pilot clinical trial (ART-PRO)
Mutation
413 32411655 An Innovative Sequence-to-Structure-Based Approach to Drug Resistance Interpretation and Prediction: The Use of Molecular Interaction Fields to Detect HIV-1 Protease Binding-Site Dissimilarities
Mutation
414 32413134 Differential detection of M184V/I between plasma historical HIV genotypes and HIV proviral DNA from PBMCs
Mutation
415 32434561 Pretreatment resistance mutations and treatment outcomes in adults living with HIV-1: a cohort study in urban Malawi
Mutation
416 32438914 Efficacy and safety of abacavir/lamivudine plus rilpivirine as a first-line regimen in treatment-naive HIV-1 infected adults
Mutation
417 32446377 Critical role of PP2A-B56 family protein degradation in HIV-1 Vif mediated G2 cell cycle arrest
Mutation
418 32457241 The HIV-1 Env gp120 Inner Domain Shapes the Phe43 Cavity and the CD4 Binding Site
Mutation
419 32464638 In vitro susceptibility to fostemsavir is not affected by long-term exposure to antiviral therapy in MDR HIV-1-infected patients
Mutation
420 32475121 High Levels of Acquired HIV Drug Resistance Following Virological Nonsuppression in HIV-Infected Women from a High-Risk Cohort in Uganda
Mutation
421 32481261 Escalating and sustained immunovirological dissociation among antiretroviral drug-experienced perinatally human immunodeficiency virus-1-infected children and adolescents living in the Central African Republic: A STROBE-compliant study
Mutation
422 32493197 Application of Structure-based Methods to Analyze Resistance Mutations for Chemically Diverse Non-Nucleoside Reverse Transcriptase Inhibitors
Mutation
423 32510047 HIGH-FREQUENCY failure of combination antiretroviral therapy in paediatric HIV infection is associated with unmet maternal needs causing maternal NON-ADHERENCE
Mutation
424 32522826 Diagnostic Accuracy of Pan-Degenerate Amplification and Adaptation Assay for HIV-1 Drug Resistance Mutation Analysis in Low- and Middle-Income Countries
Mutation
425 32528834 Exploring the hydrophobic channel of NNIBP leads to the discovery of novel piperidine-substituted thiophene[3,2-d]pyrimidine derivatives as potent HIV-1 NNRTIs
Mutation
426 32538781 HIV-1 Vpr induces cell cycle arrest and enhances viral gene expression by depleting CCDC137
Mutation
427 32541474 Two treatment strategies for management of Neurosymptomatic cerebrospinal fluid HIV escape in Pune, India
Mutation
428 32545337 Daxx Inhibits HIV-1 Reverse Transcription and Uncoating in a SUMO-Dependent Manner
Mutation
429 32553106 MxB sensitivity of HIV-1 is determined by a highly variable and dynamic capsid surface
Mutation
430 32555643 HIV-1 re-suppression on a first-line regimen despite the presence of phenotypic drug resistance
Mutation
431 32556165 HIV-1 Gag mutations alone are sufficient to reduce darunavir susceptibility during virological failure to boosted PI therapy
Mutation
432 32576136 Prevalence and determinants of virological failure, genetic diversity and drug resistance among people living with HIV in a minority area in China: a population-based study
Mutation
433 32601157 HIV-1 Integrase Inhibitors That Are Active against Drug-Resistant Integrase Mutants
Mutation
434 32605062 Multi-Laboratory Comparison of Next-Generation to Sanger-Based Sequencing for HIV-1 Drug Resistance Genotyping
Mutation
435 32629687 Occurrence of the S230R integrase strand inhibitor mutation in a treatment-naive individual case report
Mutation
436 32631509 Discovery of potential dual-target prodrugs of HIV-1 reverse transcriptase and nucleocapsid protein 7
Mutation
437 32640577 Targeting HIV-1 RNase H: N'-(2-Hydroxy-benzylidene)-3,4,5-Trihydroxybenzoylhydrazone as Selective Inhibitor Active against NNRTIs-Resistant Variants
Mutation
438 32642769 Persistent low-level viraemia in antiretroviral treatment-experienced patients is not linked to viral resistance or inadequate drug concentrations
Mutation
439 32643196 Structural investigation of 2-naphthyl phenyl ether inhibitors bound to WT and Y181C reverse transcriptase highlights key features of the NNRTI binding site
Mutation
440 32663847 Near Real-Time Identification of Recent Human Immunodeficiency Virus Transmissions, Transmitted Drug Resistance Mutations, and Transmission Networks by Multiplexed Primer ID-Next-Generation Sequencing in North Carolina
Mutation
441 32665593 HIV-1 replication complexes accumulate in nuclear speckles and integrate into speckle-associated genomic domains
Mutation
442 32669335 A Rare Mutation in an Infant-Derived HIV-1 Envelope Glycoprotein Alters Interprotomer Stability and Susceptibility to Broadly Neutralizing Antibodies Targeting the Trimer Apex
Mutation
443 32669382 A Comprehensive Genomics Solution for HIV Surveillance and Clinical Monitoring in Low-Income Settings
Mutation
444 32692778 Pre-treatment drug resistance and HIV-1 genetic diversity in the rural and urban settings of Northwest-Cameroon
Mutation
445 32701823 Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) From Dolutegravir (DTG)+F/TAF or DTG+F/Tenofovir Disoproxil Fumarate (TDF) in the Presence of Pre-existing NRTI Resistance
Mutation
446 32709248 Transmitted drug resistance mutations and subtype diversity amongst HIV-1 sero-positive voluntary blood donors in Accra, Ghana
Mutation
447 32711474 Immune escape mutations in HIV-1 controllers in the Brazilian Amazon region
Mutation
448 32712537 Bioisosterism-based design and enantiomeric profiling of chiral hydroxyl-substituted biphenyl-diarylpyrimidine nonnucleoside HIV-1 reverse transcriptase inhibitors
Mutation
449 32715952 Pooled resistance analyses of darunavir once-daily regimens and formulations across 10 clinical studies of treatment-naive and treatment-experienced patients with human immunodeficiency virus-1 infection
Mutation
450 32747359 Nucleocapsid Protein Precursors NCp9 and NCp15 Suppress ATP-Mediated Rescue of AZT-Terminated Primers by HIV-1 Reverse Transcriptase
Mutation
451 32752001 Genetic Features of HIV-1 Integrase Sub-Subtype A6 Predominant in Russia and Predicted Susceptibility to INSTIs
Mutation
452 32753492 HIV Vpr Modulates the Host DNA Damage Response at Two Independent Steps to Damage DNA and Repress Double-Strand DNA Break Repair
Mutation
453 32756581 Survival among antiretroviral-experienced HIV-2 patients experiencing virologic failure with drug resistance mutations in Cote d'Ivoire West Africa
Mutation
454 32761071 Human Immunodeficiency Virus (HIV) Drug Resistance, Phylogenetic Analysis, and Superinfection Among Men Who Have Sex with Men and Transgender Women in Sub-Saharan Africa: HIV Prevention Trials Network (HPTN) 075 Study
Mutation
455 32778120 Impact of HIV-1 Vpr manipulation of the DNA repair enzyme UNG2 on B lymphocyte class switch recombination
Mutation
456 32804970 Prevalence and characteristics of HIV drug resistance among antiretroviral treatment (ART) experienced adolescents and young adults living with HIV in Ndola, Zambia
Mutation
457 32824587 Y44A Mutation in the Acidic Domain of HIV-2 Tat Impairs Viral Reverse Transcription and LTR-Transactivation
Mutation
458 32843050 First case of Dolutegravir and Darunavir/r multi drug-resistant HIV-1 in Cameroon following exposure to Raltegravir: lessons and implications in the era of transition to Dolutegravir-based regimens
Mutation
459 32852081 Disrupting HIV-1 capsid formation causes cGAS sensing of viral DNA
Mutation
460 32853364 Accumulation of integrase strand transfer inhibitor resistance mutations confers high-level resistance to dolutegravir in non-B subtype HIV-1 strains from patients failing raltegravir in Uganda
Mutation
461 32858802 Structural Comparison of Diverse HIV-1 Subtypes using Molecular Modelling and Docking Analyses of Integrase Inhibitors
Mutation
462 32873061 Prevalence of Antiretroviral Drug Resistance Mutations Among Pretreatment and Antiretroviral Therapy-Failure HIV Patients in Uzbekistan
Mutation
463 32874468 Detection of human immunodeficiency virus type 1 transmitted drug resistance among treatment-naive individuals residing in Jakarta, Indonesia
Mutation
464 32877546 From Hospital to the Community: Redesigning the Human Immunodeficiency Virus (HIV) Clinical Service Model to Respond to an Outbreak of HIV Among People Who Inject Drugs
Mutation
465 32879304 Broadly neutralizing plasma antibodies effective against autologous circulating viruses in infants with multivariant HIV-1 infection
Mutation
466 32883642 New indolylarylsulfone non-nucleoside reverse transcriptase inhibitors show low nanomolar inhibition of single and double HIV-1 mutant strains
Mutation
467 32894102 HIV-1 infection among women in Israel, 2010-2018
Mutation
468 11157057 Clustered mutations in HIV-1 gag are consistently required for escape from HLA-B27-restricted cytotoxic T lymphocyte responses
Mutation
469 32925973 Variation in HIV-1 Nef function within and among viral subtypes reveals genetically separable antagonism of SERINC3 and SERINC5
Mutation
470 32929472 Primary resistance to integrase strand transfer inhibitors in Spain using ultrasensitive HIV-1 genotyping
Mutation
471 32946725 Drug Resistance Spread in 6 Metropolitan Regions, Germany, 2001-2018(1)
Mutation
472 11581417 Human immunodeficiency virus type 1 env sequences from Calcutta in eastern India: identification of features that distinguish subtype C sequences in India from other subtype C sequences
Mutation
473 32954411 Prevalence of integrase strand transfer inhibitor resistance mutations in antiretroviral-naive HIV-1-infected individuals in Cameroon
Mutation
474 11737863 Analysis of HIV-1 drug resistant mutations by line probe assay and direct sequencing in a cohort of therapy naive HIV-1 infected Italian patients
Mutation
475 32960906 Few amino acid signatures distinguish HIV-1 subtype B pandemic and non-pandemic strains
Mutation
476 32964671 Transmitted drug resistance to NRTIs and risk of virological failure in naive patients treated with integrase inhibitors
Mutation
477 32974383 Evidence for Disruption of Mg(2+) Pair as a Resistance Mechanism Against HIV-1 Integrase Strand Transfer Inhibitors
Mutation
478 32974670 In vitro cross-resistance to doravirine in a panel of HIV-1 clones harbouring multiple NNRTI resistance mutations
Mutation
479 32977301 Targeting dual tolerant regions of binding pocket: Discovery of novel morpholine-substituted diarylpyrimidines as potent HIV-1 NNRTIs with significantly improved water solubility
Mutation
480 32978684 In vivo drug resistance mutation dynamics from the early to chronic stage of infection in antiretroviral-therapy-naive HIV-infected men who have sex with men
Mutation
481 32986709 Patterns of acquired HIV-1 drug resistance mutations and predictors of virological failure in Moshi, Northern Tanzania
Mutation
482 32993693 Increased HIV-1 pretreatment drug resistance with consistent clade homogeneity among ART-naive HIV-1 infected individuals in Ethiopia
Mutation
483 33014372 Virologic suppression in patients with a documented M184V/I mutation based on the number of active agents in the antiretroviral regimen
Mutation
484 12657161 Prevalence of genotypic HIV-1 drug resistance in Thailand, 2002
Mutation
485 33031103 Critical effect of Pol escape mutations associated with detrimental allele HLA-C*15: 05 on clinical outcome in HIV-1 subtype A/E infection
Mutation
486 33031315 Differences in human immunodeficiency virus-1C viral load and drug resistance mutation between plasma and cerebrospinal fluid in patients with human immunodeficiency virus-associated cryptococcal meningitis in Botswana
Mutation
487 33037235 Virological outcome among HIV infected patients transferred from pediatric care to adult units in Madrid, Spain (1997-2017)
Mutation
488 33085662 Predominance of positive epistasis among drug resistance-associated mutations in HIV-1 protease
Mutation
489 33093566 Nanoscale flow cytometry reveals interpatient variability in HIV protease activity that correlates with viral infectivity and identifies drug-resistant viruses
Mutation
490 33119663 Antiretroviral drug use and HIV drug resistance in female sex workers in Tanzania and the Dominican Republic
Mutation
491 33122923 Transmitted and Acquired HIV-1 Drug Resistance from a Family: A Case Study
Mutation
492 33136738 High Prevalence of HIV-1 Drug Resistance and Dynamics of Transmission Among High-Risk Populations in Port-au-Prince, Haiti
Mutation
493 33136751 Long-Acting Injectable Cabotegravir + Rilpivirine for HIV Maintenance Therapy: Week 48 Pooled Analysis of Phase 3 ATLAS and FLAIR Trials
Mutation
494 33143301 Increasing Prevalence of HIV-1 Transmitted Drug Resistance in Portugal: Implications for First Line Treatment Recommendations
Mutation
495 33143469 Scaffold hopping and optimisation of 3',4'-dihydroxyphenyl- containing thienopyrimidinones: synthesis of quinazolinone derivatives as novel allosteric inhibitors of HIV-1 reverse transcriptase-associated ribonuclease H
Mutation
496 33144375 In Vivo Emergence of a Novel Protease Inhibitor Resistance Signature in HIV-1 Matrix
Mutation
497 33146906 HIV-1 infection of CD4 T cells impairs antigen-specific B cell function
Mutation
498 33166562 HIV-1 gp41 genetic diversity and enfuvirtide resistance-associated mutations among enfuvirtide-naive patients in southern China
Mutation
499 33170863 Efficacy and safety of dolutegravir plus emtricitabine versus standard ART for the maintenance of HIV-1 suppression: 48-week results of the factorial, randomized, non-inferiority SIMPL'HIV trial
Mutation
500 33173092 Impaired ability of Nef to counteract SERINC5 is associated with reduced plasma viremia in HIV-infected individuals
Mutation
501 33175558 Multiple Molecular Dynamics Simulations of the Inhibitor GRL-02031 Complex with Wild Type and Mutant HIV-1 Protease Reveal the Binding and Drug-Resistance Mechanism
Mutation
502 33184634 Progressive emergence of an S153F plus R263K combination of integrase mutations in the proviral DNA of one individual successfully treated with dolutegravir
Mutation
503 33196554 Simulating HIV Breakthrough and Resistance Development During Variable Adherence to Antiretroviral Treatment
Mutation
504 33200210 Long-term efficacy of dolutegravir plus lamivudine for maintenance of HIV viral suppression in adults with and without historical resistance to lamivudine: Week 96 results of ART-PRO pilot study
Mutation
505 33204746 Treatment Switch to Dolutegravir With 2 Nucleoside Reverse-Transcriptase Inhibitors (NRTI) in Comparison to Continuation With Protease Inhibitor/Ritonavir Among Patients With Human Immunodeficiency Virus at Risk for Prior NRTI Resistance: A Cohort Analysis of Real-World Data
Mutation
506 33217873 Impact of previous HIV resistance and virologic failures on virologic outcome following a switch to dolutegravir with 2 NRTIs among people living with HIV
Mutation
507 33228206 Emergence of Resistance to Integrase Strand Transfer Inhibitors during Dolutegravir Containing Triple-Therapy in a Treatment-Experienced Patient with Pre-Existing M184V/I Mutation
Mutation
508 33246440 Identification and differential expression of serotransferrin and apolipoprotein A-I in the plasma of HIV-1 patients treated with first-line antiretroviral therapy
Mutation
509 33247553 Incentives conditioned on tenofovir levels to support PrEP adherence among young South African women: a randomized trial
Mutation
510 33252379 Efficacy and safety of the long-acting fusion inhibitor albuvirtide in antiretroviral-experienced adults with human immunodeficiency virus-1: interim analysis of the randomized, controlled, phase 3, non-inferiority TALENT study
Mutation
511 33253162 Pre-existing resistance in the latent reservoir can compromise VRC01 therapy during chronic HIV-1 infection
Mutation
512 33262331 Reduced efficacy of HIV-1 integrase inhibitors in patients with drug resistance mutations in reverse transcriptase
Mutation
513 33285702 Genotyping and antiretroviral drug resistance of human immunodeficiency Virus-1 in Jazan, Saudi Arabia
Mutation
514 33287618 First Assessment of Acquired HIV-1 Drug Resistance and Mutation Patterns in Suriname
Mutation
515 33287631 Near Full-Length Genomic Characterization of a Novel HIV-1 B/C Recombinant Form Identified in Guangdong Province, China
Mutation
516 33290394 RV144 HIV-1 vaccination impacts post-infection antibody responses
Mutation
517 33297399 HIV-1C env and gag Variation in the Cerebrospinal Fluid and Plasma of Patients with HIV-Associated Cryptococcal Meningitis in Botswana
Mutation
518 33300183 Week 96 resistance analyses of the once-daily, single-tablet regimen (STR) darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in adults living with HIV-1 from the phase 3 randomized AMBER and EMERALD trials
Mutation
519 33315694 Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in Adults With HIV and M184V/I Mutation
Mutation
520 33324078 Absence of Integrase Inhibitor-Associated Resistance Among Antiretroviral Therapy-Naive HIV-1-Infected Adults in Guangdong Province, China, in 2018
Mutation
521 33329467 Epidemiological and Molecular Characteristics of HIV-1 Infection in a Sample of Men Who Have Sex With Men in Brazil: Phylogeography of Major Subtype B and F1 Transmission Clusters
Mutation
522 33329900 Clinical outcomes of HIV-1 infected patients switched from complex multi-tablet regimens to tenofovir alafenamide based single-tablet regimens plus a boosted protease inhibitor in a real-world setting
Mutation
523 33347449 The genotype distribution, infection stage and drug resistance mutation profile of human immunodeficiency virus-1 among the infected blood donors from five Chinese blood centers, 2014-2017
Mutation
524 33352387 Novel indolylarylsulfone derivatives as covalent HIV-1 reverse transcriptase inhibitors specifically targeting the drug-resistant mutant Y181C
Mutation
525 33364799 Prevalence of HIV-1 Integrase Strand Transfer Inhibitor Resistance in Treatment-Naive Voluntary Counselling and Testing Clients by Population Sequencing and Illumina Next-Generation Sequencing in Taiwan
Mutation
526 33369017 Transmitted HIV-1 drug resistance in a large international cohort using next-generation sequencing: results from the Strategic Timing of Antiretroviral Treatment (START) study
Mutation
527 33409332 A Low Level of Darunavir Resistance-Associated Mutation Emergence in Patients With Virological Failure During Long-term Use of Darunavir in People With HIV. The ANRS CO3 Aquitaine Cohort
Mutation
528 33462791 HIV-1C and HIV-1B Tat protein polymorphism in Southern Brazil
Mutation
529 33477685 Analysis and Molecular Determinants of HIV RNase H Cleavage Specificity at the PPT/U3 Junction
Mutation
530 33478415 Increase in HIV-1-transmitted drug resistance among ART-naive youths at the China-Myanmar border during 2009 ~ 2017
Mutation
531 33480094 Virological response and resistance profile in highly treatment-experienced HIV-1-infected patients switching to dolutegravir plus boosted darunavir in clinical practice
Mutation
532 33481784 DEER-PREdict: Software for efficient calculation of spin-labeling EPR and NMR data from conformational ensembles
Mutation
533 33485964 Structural characterization of HIV-1 matrix mutants implicated in envelope incorporation
Mutation
534 15067030 Immune selection for altered antigen processing leads to cytotoxic T lymphocyte escape in chronic HIV-1 infection
Mutation
535 33503916 Structural Impacts of Drug-Resistance Mutations Appearing in HIV-2 Protease
Mutation
536 15839752 Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: results of a global collaboration
Mutation
537 33503987 Molecular Transmission Dynamics of Primary HIV Infections in Lazio Region, Years 2013-2020
Mutation
538 33505382 Non-synonymous Substitutions in HIV-1 GAG Are Frequent in Epitopes Outside the Functionally Conserved Regions and Associated With Subtype Differences
Mutation
539 33508465 Design and exploration of C-3 benzoic acid bioisosteres and alkyl replacements in the context of GSK3532795 (BMS-955176) that exhibit broad spectrum HIV-1 maturation inhibition
Mutation
540 33515546 Ceramide synthase 2 deletion decreases the infectivity of HIV-1
Mutation
541 33557775 HIV drug resistance and HIV transmission risk factors among newly diagnosed individuals in Southwest China
Mutation
542 33561143 HIV incidence after pre-exposure prophylaxis initiation among women and men at elevated HIV risk: A population-based study in rural Kenya and Uganda
Mutation
543 33567378 Identification of novel potent HIV-1 inhibitors by exploiting the tolerant regions of the NNRTIs binding pocket
Mutation
544 33592343 Transmitted drug resistance among HIV-1 drug-naive patients in Greece
Mutation
545 33603155 PANDAA intentionally violates conventional qPCR design to enable durable, mismatch-agnostic detection of highly polymorphic pathogens
Mutation
546 33624081 Deep sequencing analysis of M184V/I mutation at the switch and at the time of virological failure of boosted protease inhibitor plus lamivudine or boosted protease inhibitor maintenance strategy (substudy of the ANRS-MOBIDIP trial)
Mutation
547 33632139 Increased acquired protease inhibitor drug resistance mutations in minor HIV-1 quasispecies from infected patients suspected of failing on national second-line therapy in South Africa
Mutation
548 33635845 Pre-treatment integrase inhibitor resistance is uncommon in antiretroviral therapy-naive individuals with HIV-1 subtype A1 and D infections in Uganda
Mutation
549 33649107 Long Dissociation of Bictegravir from HIV-1 Integrase-DNA Complexes
Mutation
550 16054592 L565M mutation in HIV-1 glycoprotein 41 stabilizes the coiled-coil structure
Mutation
551 33654530 Prevalence of human immunodeficiency virus-1 drug-resistant mutations among adults on first- and second-line antiretroviral therapy in a resource-limited health facility in Busia County, Kenya
Mutation
552 16201018 Natural variation in Vif: differential impact on APOBEC3G/3F and a potential role in HIV-1 diversification
Mutation
553 33668946 HIV Drug Resistance Mutations Detection by Next-Generation Sequencing during Antiretroviral Therapy Interruption in China
Mutation
554 33679129 Low Frequency of Integrase Inhibitor Resistance Mutations Among Therapy-Naive HIV Patients in Southeast China
Mutation
555 33683148 Integrase Strand Transfer Inhibitor Resistance in Integrase Strand Transfer Inhibitor-Naive Persons
Mutation
556 33686573 Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed People with HIV Aged >/= 65 Years: Week 48 Results of a Phase 3b, Open-Label Trial
Mutation
557 33688632 One-step sequence and structure-guided optimization of HIV-1 envelope gp140
Mutation
558 33692109 A stable immature lattice packages IP(6) for HIV capsid maturation
Mutation
559 33693680 No difference in HIV-1 integrase inhibitor resistance between CSF and blood compartments
Mutation
560 33722682 Dolutegravir response in antiretroviral therapy naive and experienced patients with M184V/I: Impact in low-and middle-income settings
Mutation
561 33724373 Tenofovir disoproxil fumarate and emtricitabine maintenance strategy in virologically controlled adults with low HIV-1 DNA: 48 week results from a randomized, open-label, non-inferiority trial
Mutation
562 33734374 Prevalence of M184V and K65R in proviral DNA from PBMCs in HIV-infected youths with lamivudine/emtricitabine exposure
Mutation
563 33735301 Virological failure and antiretroviral resistance among HIV-infected children after five years follow-up in the ANRS 12225-PEDIACAM cohort in Cameroon
Mutation
564 16524459 DR_SEQAN: a PC/Windows-based software to evaluate drug resistance using human immunodeficiency virus type 1 genotypes
Mutation
565 33754285 (1)H, (13)C and (15)N backbone resonance assignment of HIV-1 Gag (276-432) encompassing the C-terminal domain of the capsid protein, the spacer peptide 1 and the nucleocapsid protein
Mutation
566 33787846 Synergy and allostery in ligand binding by HIV-1 Nef
Mutation
567 33788308 HIV-1 subtypes and drug resistance in children during antiretroviral therapy in Brazil
Mutation
568 33800269 Short Communication: Integrase Strand Transfer Inhibitors Drug Resistance Mutations in Puerto Rico HIV-Positive Individuals
Mutation
569 33800773 Nef Obtained from Individuals with HIV-1 Vary in Their Ability to Antagonize SERINC3- and SERINC5-Mediated HIV-1 Restriction
Mutation
570 33805099 Acquired HIV-1 Protease Conformational Flexibility Associated with Lopinavir Failure May Shape the Outcome of Darunavir Therapy after Antiretroviral Therapy Switch
Mutation
571 33807382 HIV-1 Subtype C Drug Resistance Mutations in Heavily Treated Patients Failing Integrase Strand Transfer Inhibitor-Based Regimens in Botswana
Mutation
572 33832362 E-pharmacophore based screening to identify potential HIV-1 gp120 and CD4 interaction blockers for wild and mutant types
Mutation
573 33836787 A single G10T polymorphism in HIV-1 subtype C Gag-SP1 regulates sensitivity to maturation inhibitors
Mutation
574 33844760 [Prevalence of transmitted drug resistance in HIV-infected treatment-naive patients in Chile]
Mutation
575 33854982 Priority Intervention Targets Identified Using an In-Depth Sampling HIV Molecular Network in a Non-Subtype B Epidemics Area
Mutation
576 33855355 Intermittent two-drug antiretroviral therapies maintain long-term viral suppression in real life in highly experienced HIV-infected patients
Mutation
577 33857166 High drug resistance levels could compromise the control of HIV infection in paediatric and adolescent population in Kinshasa, the Democratic Republic of Congo
Mutation
578 33862046 Variations in Env at amino acids 328 and 330 affect HIV-1 replicative fitness and entry inhibitor sensitivity
Mutation
579 33863979 CryoET structures of immature HIV Gag reveal six-helix bundle
Mutation
580 33872329 Mechanisms of HIV-1 evasion to the antiviral activity of chemokine CXCL12 indicate potential links with pathogenesis
Mutation
581 33880558 Three-year study of pre-existing drug resistance substitutions and efficacy of bictegravir/emtricitabine/tenofovir alafenamide in HIV-1 treatment-naive participants
Mutation
582 33892628 Interaction analysis of statistically enriched mutations identified in Cameroon recombinant subtype CRF02_AG that can influence the development of Dolutegravir drug resistance mutations
Mutation
583 16956392 HIV-2 Protease resistance defined in yeast cells
Mutation
584 33941212 Virologic outcomes of switching to dolutegravir functional mono- or dual therapy with a non-cytosine nucleoside analog: a retrospective study of treatment-experienced, patients living with HIV
Mutation
585 33943000 Is there a role for doravirine in African HIV treatment programmes? A large observational resistance study in South Africa
Mutation
586 16970827 Cytotoxic T cell recognition of an HIV-1 reverse transcriptase variant peptide incorporating the K103N drug resistance mutation
Mutation
587 33952315 Subtype-specific differences in Gag-protease replication capacity of HIV-1 isolates from East and West Africa
Mutation
588 33979774 Design, synthesis and anti-HIV evaluation of novel 5-substituted diarylpyrimidine derivatives as potent HIV-1 NNRTIs
Mutation
589 34015097 Prevalence of genotypic baseline risk factors for cabotegravir + rilpivirine failure among ARV-naive patients
Mutation
590 34069929 Nationwide Study of Drug Resistance Mutations in HIV-1 Infected Individuals under Antiretroviral Therapy in Brazil
Mutation
591 17280617 Baseline resistance to nucleoside reverse transcriptase inhibitors fails to predict virologic response to combination therapy in children (PACTG 338)
Mutation
592 34074135 Surveillance of Pretreatment Drug Resistance Among HIV-Infected Children in Ibadan, Nigeria
Mutation
593 34085506 Reverse transcriptase and protease inhibitors mutational viral load in HIV infected pregnant women with transmitted drug resistance in Argentina
Mutation
594 17311088 Sequential broadening of CTL responses in early HIV-1 infection is associated with viral escape
Mutation
595 34107774 Drug Resistance Mutations in a Population Before Antiretroviral Therapy Initiation in Northern South Africa
Mutation
596 34151963 HIV-1 non-group M phenotypic susceptibility in vitro to bictegravir and cabotegravir
Mutation
597 34212033 High Detection Rate of HIV Drug Resistance Mutations among Patients Who Fail Combined Antiretroviral Therapy in Manaus, Brazil
Mutation
598 34243716 Transmitted drug resistance to Tenofovir/Emtricitabine among persons with newly diagnosed HIV infection in Shenyang city, Northeast China from 2016 to 2018
Mutation
599 34278422 Feasibility and clinical relevance of HIV-1 drug resistance testing in patients with low-level viraemia in South Africa
Mutation
600 34279816 Prevalence of integrase strand transfer inhibitor (INSTIs) resistance mutations in Henan Province, China (2018-2020)
Mutation
601 34353064 Evaluation of minor drug-resistant viral variants in patients experiencing virological failure (VF) on a first-line regimen in Fujian Province by high-throughput sequencing
Mutation
602 34369051 Dolutegravir in the long term in children and adolescents: frequent virological failure but rare acquired genotypic resistance
Mutation
603 34402512 Distribution characteristics of drug resistance mutations of HIV CRF01_AE, CRF07_BC and CRF08_BC from patients under ART in Ganzhou, China
Mutation
604 34622871 Prevalence and factors associated with HIV-1 drug resistance mutations in treatment-experienced patients in Nairobi, Kenya: A cross-sectional study
Mutation
605 34651192 Dolutegravir-based dual maintenance regimens combined with lamivudine/emtricitabine or rilpivirine: risk of virological failure in a real-life setting
Mutation
606 34871089 Phase 2 Open-Label Study of Long-Term Safety, Tolerability, and Antiviral Activity of Rilpivirine in Antiretroviral-Naive Adolescents Living with HIV-1
Mutation
607 34959542 HIV Pretreatment Drug Resistance Trends in Mexico City, 2017-2020
Mutation
608 35061671 Prevalence of HIV-1 drug resistance in Eastern European and Central Asian countries
Mutation
609 35061879 Impact of combinations of clinically observed HIV integrase mutations on phenotypic resistance to integrase strand transfer inhibitors (INSTIs): a molecular study
Mutation
610 35107140 Prevalence and patterns of HIV drug resistance in patients with suspected virological failure in North-Western Tanzania
Mutation
611 35222867 The frequency of HIV-1 infection and surveillance drug-resistant mutations determination among Iranians with high-risk behaviors, during 2014 to 2020
Mutation
612 35229630 High Rate of HIV-1 Drug Resistance in Antiretroviral Therapy-Failure Patients in Liaoning Province, China
Mutation
613 35240975 Integrase Strand Transfer Inhibitor (INSTI) Genotypic Resistance Analysis in Treatment-Naive, INSTI Free Antiretroviral-Experienced and INSTI-Experienced Turkish Patients Infected with HIV-1
Mutation
614 35274144 Integrase resistance emergence with dolutegravir/lamivudine with prior HIV-1 suppression
Mutation
615 35300056 Drug Resistance to HIV-1 Integrase Inhibitors Among Treatment-Naive Patients in Beijing, China
Mutation
616 35485331 Low prevalence of doravirine-associated resistance mutations among polish human immunodeficiency-1 (HIV-1)-infected patients
Mutation
617 35593031 Acquired HIV drug resistance among adults living with HIV receiving first-line antiretroviral therapy in Rwanda: A cross-sectional nationally representative survey
Mutation
618 35838991 Low-frequency HIV-1 drug resistance mutations in antiretroviral naive individuals in Botswana
Mutation
619 35899084 High Prevalence of Doravirine Resistance in HIV-1-Infected Patients with Virological Failure to an NNRTI-Based Single-Tablet Regimen
Mutation
620 35905753 Viral suppression and HIV-1 drug resistance 1 year after pragmatic transitioning to dolutegravir first-line therapy in Malawi: a prospective cohort study
Mutation
621 35965850 The Emergence of Resistance Under Firstline INSTI Regimens
Mutation
622 35972723 Prevalence of Drug Resistance and Genetic Transmission Networks Among Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome Patients with Antiretroviral Therapy Failure in Guangxi, China
Mutation
623 35982613 Characteristics of Human Immunodeficiency Virus (HIV) Seroconversions in a Large Prospective Implementation Cohort Study of Oral HIV Preexposure Prophylaxis in Men Who Have Sex with Men (EPIC-NSW)
Mutation
624 36016383 HIV-1 Diversity and Drug Resistance in Treatment-Naive Children and Adolescents from Rio de Janeiro, Brazil
Mutation
625 36037154 A public health approach to monitoring HIV with resistance to HIV pre-exposure prophylaxis
Mutation
626 36082606 Resistance Analyses in Highly Treatment-Experienced People With Human Immunodeficiency Virus (HIV) Treated With the Novel Capsid HIV Inhibitor Lenacapavir
Mutation
627 36130828 Molecular Basis for the Recognition of HIV Nef138-8 Epitope by a Pair of Human Public T Cell Receptors
Mutation
628 36246670 Subgenomic sequence analysis reveals emergence of new circulating recombinant forms of HIV-1 in Pakistan
Mutation
629 36246702 Frequency of resistance to first-line antiretroviral therapy observed among HIV patients
Mutation
630 36288365 Rate of virological failure and HIV-1 drug resistance among HIV-infected adolescents in routine follow-up on health facilities in Cameroon
Mutation
631 36301912 Dynamics of Rilpivirine Resistance-Associated Mutation: E138 in Reverse Transcriptase among Antiretroviral-Naive HIV-1-Infected Individuals in Turkey
Mutation
632 36441484 Efficacy of Efavirenz-Based Regimen in Antiretroviral-Naive Patients with HIV-1 V179D/E Mutations in Shanghai, China
Mutation
633 36550885 Nevirapine plasma concentration is associated with virologic failure and the emergence of drug-resistant mutations among HIV patients in Kenya: A cross sectional study
Mutation
634 36571282 Transmitted Drug Resistance to Integrase-Based First-Line Human Immunodeficiency Virus Antiretroviral Regimens in Mediterranean Europe
Mutation
635 36582452 HIV-1C in-House RNA-Based Genotyping Assay for Detection of Drug Resistance Mutations in Samples with Low-Level Viral Loads
Mutation
636 36680436 Emerging integrase strand transfer inhibitor drug resistance mutations among children and adults on ART in Tanzania: findings from a national representative HIV drug resistance survey
Mutation
637 36708768 Virologic status and pattern of drug resistance mutation among ART-experienced HIV-infected patients in Butuo County, China
Mutation
638 36756611 Prevalence of HIV Transmitted Drug Resistance in Nanjing from 2018 to 2021
Mutation
639 36870532 No transmitted drug resistance to HIV integrase strand-transfer inhibitors after their scale-up in Estonia in 2017
Mutation
640 36961945 Brief Report: Comparative Analysis of Pre-existing HIV Drug Resistance Mutations in Proviral DNA Using Next-Generation Sequencing and Routine HIV RNA Genotyping
Mutation
641 36962573 HIV-1 integrase resistance associated mutations and the use of dolutegravir in Sub-Saharan Africa: A systematic review and meta-analysis
Mutation
642 37220545 Genetic Diversity and Characteristics of Drug Resistance Among Treatment-Naive People Living with HIV in Xi'an, China
Mutation
643 37226112 Dolutegravir-associated resistance mutations after first-line treatment failure in Brazil
Mutation
644 37515095 High-Level Drug-Resistant Mutations among HIV-1 Subtype A6 and CRF02_AG in Kazakhstan
Mutation
645 37585352 Archived rilpivirine-associated resistance mutations among ART-naive and virologically suppressed people living with HIV-1 subtype C in Botswana: implications for cabotegravir/rilpivirine use
Mutation
646 37626789 HIV-1 Disease Progression and Drug Resistance Mutations among Children on First-Line Antiretroviral Therapy in Ethiopia
Mutation
647 37778156 Preliminary report of transmitted drug resistance to integrase strand chain transfer inhibitors in treatment-naive HIV infected patients
Mutation
648 37803893 HIV-1 Subtype Diversity and Factors Affecting Drug Resistance among Patients with Virologic Failure in Antiretroviral Therapy in Hainan Province, China, 2014-2020
Mutation
649 37807595 Bictegravir/emtricitabine/tenofovir alafenamide in paediatrics: Real-life experience from a French cohort (2019-2023)
Mutation
650 37854696 Development of a multiassay algorithm (MAA) to identify recent HIV infection in newly diagnosed individuals in Indonesia
Mutation
651 37941373 Prevalence and analysis of acquired and transmitted integrase strand transfer inhibitor-associated HIV-1 drug resistance in Chongqing, China
Mutation
652 38164103 Current Resistance of HIV-1 Strains Isolated in Volunteer Blood Donors in Gabon
Mutation
653 38256948 Retrospective Study on Genetic Diversity and Drug Resistance among People Living with HIV at an AIDS Clinic in Beijing
Mutation
654 38302941 Analysis of ART effects and drug resistance in adult HIV/AIDS patients in Meigu County, Liangshan Prefecture, China
Mutation
655 38442417 Prevalence of HIV Drug Resistance Mutations among Treatment-Naive People Living with HIV in a Tertiary Care Center in India
Mutation
656 38476948 High prevalence of pre-treatment and acquired HIV-1 drug resistance mutations among non-citizens living with HIV in Botswana
Mutation
657 38484128 Type 1 Human Immunodeficiency Virus (HIV-1) Incidence, Adherence, and Drug Resistance in Individuals Taking Daily Emtricitabine/Tenofovir Disoproxil Fumarate for HIV-1 Pre-exposure Prophylaxis: Pooled Analysis From 72 Global Studies
Mutation
658 38551451 Drug resistance and influencing factors in HIV-1-infected individuals under antiretroviral therapy in Guangxi, China
Mutation
659 38608935 Emergence of HIV-1 drug resistance mutations among children and adolescents undergoing prolonged antiretroviral therapy in Guangxi
Mutation
660 38618279 Outcome of Darunavir-Cobicistat-Based Regimens in HIV-Infected People Who Have Experienced Virological Failure
Mutation
661 38748464 Pharmaco-virological Outcomes and Genotypic Resistance Profiles Among Children and Adolescents Receiving a Dolutegravir-Based Regimen in Togo
Mutation
662 38934465 Prevalence and transmission of pretreatment drug resistance in people living with HIV-1 in Shanghai China, 2017-2021
Mutation
663 38959124 HIV-1 Molecular Networks and Pretreatment Drug Resistance at the Frontier of Yunnan Province, China
Mutation
664 39041595 Transmitted Antiretroviral Drug Resistance to Integrase Strand Transfer Inhibitors Class in Sao Paulo Metropolitan Area, Brazil
Mutation
665 39079031 HIV Drug Resistance in Newly Diagnosed Young Children in the Western Cape, South Africa
Mutation
666 39086253 HIV-1 Integrase T218I/S Polymorphisms Do Not Reduce HIV-1 Integrase Inhibitors' Phenotypic Susceptibility
Mutation
667 39226273 HIV-1 residual risk and pre-treatment drug resistance among blood donors: A sentinel surveillance from Gabon
Mutation
668 39229286 First Case of HIV Seroconversion With Integrase Resistance Mutations on Long-Acting Cabotegravir for Prevention in Routine Care
Mutation
669 39240111 Short CDRL1 in intermediate VRC01-like mAbs is not sufficient to overcome key glycan barriers on HIV-1 Env
Mutation
670 39241081 Viral load suppression and HIV-1 drug resistance mutations in persons with HIV on TLD/TAFED in Zambia
Mutation
671 39272106 HIV drug resistance: analysis of viral genotypes and mutation loci in people living with HIV in Chongqing, China (2016-2023)
Mutation
672 39286902 DORA: 48-week weight and metabolic changes in Black women with HIV, in a phase IIIb switch study from dolutegravir- or efavirenz- to doravirine-based first-line antiretroviral therapy
Mutation
673 39301743 Oral HIV pre-exposure prophylaxis use and resistance-associated mutations among men who have sex with men and transgender persons newly diagnosed with HIV in the Netherlands: results from the ATHENA cohort, 2018 to 2022
Mutation
674 39322986 Detection of Antiretroviral Drug-Resistant Mutations and HIV-1 Subtypes in Circulation Among Men Who Have Sex With Men, SEM Females, and Female Sex Workers: Results of Vietnam's HIV Sentinel Surveillance Plus System, 2018-2020
Mutation
675 39339930 Next-Generation Sequencing Reveals a High Frequency of HIV-1 Minority Variants and an Expanded Drug Resistance Profile among Individuals on First-Line ART
Mutation
676 39339969 K103N, V106M and Y188L Significantly Reduce HIV-1 Subtype C Phenotypic Susceptibility to Doravirine
Mutation
677 39364496 Virologic Failure, Clinical Characteristics, and Common Viral Mutations in HIV Patients From Southwestern Colombia: A Nested Case-Control Study
Mutation
678 39364596 Integrase strand transfer inhibitors resistance-associated mutations in HIV-infected pregnant women
Mutation
679 39370775 High efficacy of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in Black adults in the United States, including those with pre-existing HIV resistance and suboptimal adherence
Mutation
680 39377030 Lack of Resistance Mutations to the Novel HIV-1 Capsid Inhibitor Lenacapavir Among People Living with HIV in Guangdong, China
Mutation
681 39404354 The structural and mechanistic bases for the viral resistance to allosteric HIV-1 integrase inhibitor pirmitegravir
Mutation
682 17262715 Recurrent HIV-1 integration at the BACH2 locus in resting CD4+ T cell populations during effective highly active antiretroviral therapy
Integration
683 23953889 HIV latency and integration site placement in five cell-based models
Integration
684 24968937 HIV latency. Specific HIV integration sites are linked to clonal expansion and persistence of infected cells
Integration
685 15163705 Resting CD4+ T cells from human immunodeficiency virus type 1 (HIV-1)-infected individuals carry integrated HIV-1 genomes within actively transcribed host genes
Integration
686 26912621 HIV Integration Site Analysis of Cellular Models of HIV Latency with a Probe-Enriched Next-Generation Sequencing Assay
Integration
687 25011556 HIV latency. Proliferation of cells with HIV integrated into cancer genes contributes to persistent infection
Integration
688 30024859 HIV-1 proviral landscapes distinguish posttreatment controllers from noncontrollers
Integration
689 30688658 Intact HIV-1 proviruses accumulate at distinct chromosomal positions during prolonged antiretroviral therapy
Integration
690 12843741 HIV insertions within and proximal to host cell genes are a common finding in tissues containing high levels of HIV DNA and macrophage-associated p24 antigen expression
Integration
691 28086908 HIV integration sites in latently infected cell lines: evidence of ongoing replication
Integration
692 31776247 Combined HIV-1 sequence and integration site analysis informs viral dynamics and allows reconstruction of replicating viral ancestors
Integration
693 31217357 Clones of infected cells arise early in HIV-infected individuals
Integration
694 33318172 HIV proviral DNA integration can drive T cell growth ex vivo
Integration
695 33823910 PCIP-seq: simultaneous sequencing of integrated viral genomes and their insertion sites with long reads
Integration
Contents
Description
Disease Group Note
  • The label in Group indicates that the disease is mentioned in mutation or integration research. Click the eye label to view the corresponding module information.